<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2680853-A1" country="EP" doc-number="2680853" kind="A1" date="20140108" family-id="46757317" file-reference-id="257532" date-produced="20180823" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146586808" ucid="EP-2680853-A1"><document-id><country>EP</country><doc-number>2680853</doc-number><kind>A1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12752174-A" is-representative="NO"><document-id mxw-id="PAPP154849000" load-source="docdb" format="epo"><country>EP</country><doc-number>12752174</doc-number><kind>A</kind><date>20120228</date><lang>EN</lang></document-id><document-id mxw-id="PAPP215873416" load-source="docdb" format="original"><country>EP</country><doc-number>12752174.8</doc-number><date>20120228</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140551076" ucid="CA-2012000175-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>CA</country><doc-number>2012000175</doc-number><kind>W</kind><date>20120228</date></document-id></priority-claim><priority-claim mxw-id="PPC140547299" ucid="US-201161447362-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>201161447362</doc-number><kind>P</kind><date>20110228</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL2093536624" load-source="docdb">C07D 417/06        20060101ALI20140630BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2093537570" load-source="docdb">G01N  33/48        20060101ALI20140630BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2093537998" load-source="docdb">A61P  35/02        20060101ALI20140630BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2093542600" load-source="docdb">C12Q   1/02        20060101ALI20140630BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2093542696" load-source="docdb">C12Q   1/68        20060101ALI20140630BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2093544159" load-source="docdb">A61K  31/5415      20060101AFI20140630BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1890320632" load-source="docdb" scheme="CPC">G01N2800/56        20130101 LA20161004BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1890320633" load-source="docdb" scheme="CPC">G01N2800/52        20130101 LA20161004BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1890320634" load-source="docdb" scheme="CPC">G01N2500/10        20130101 LA20161004BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1890320635" load-source="docdb" scheme="CPC">G01N  33/9413      20130101 LI20161004BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1890320636" load-source="docdb" scheme="CPC">G01N  33/57426     20130101 LI20161004BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989620036" load-source="docdb" scheme="CPC">G01N  33/57492     20130101 LI20130426BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989626847" load-source="docdb" scheme="CPC">A61K  31/5415      20130101 FI20130426BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989635157" load-source="docdb" scheme="CPC">C12Q   1/6886      20130101 LI20131205BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989642627" load-source="docdb" scheme="CPC">G01N  33/574       20130101 LI20130426BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989648864" load-source="docdb" scheme="CPC">G01N  33/57496     20130101 LI20130426BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989652431" load-source="docdb" scheme="CPC">G01N  33/5011      20130101 LI20130426BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132365057" lang="DE" load-source="patent-office">BEHANDLUNG VON KREBS MIT DOPAMINREZEPTOR-ANTAGONISTEN</invention-title><invention-title mxw-id="PT132365058" lang="EN" load-source="patent-office">TREATMENT OF CANCER WITH DOPAMINE RECEPTOR ANTAGONISTS</invention-title><invention-title mxw-id="PT132365059" lang="FR" load-source="patent-office">TRAITEMENT DU CANCER PAR DES ANTAGONISTES DES RÉCEPTEURS DOPAMINERGIQUES</invention-title><citations><patent-citations><patcit mxw-id="PCIT257153675" load-source="docdb" ucid="US-20040072824-A1"><document-id format="epo"><country>US</country><doc-number>20040072824</doc-number><kind>A1</kind><date>20040415</date></document-id><sources><source name="SEA" category="X" created-by-npl="N"/></sources></patcit></patent-citations><non-patent-citations><nplcit><text>See also references of WO  2012116432A1</text><sources><source mxw-id="PNPL48832156" load-source="docdb" name="SEA"/></sources></nplcit></non-patent-citations></citations></technical-data><parties><applicants><applicant mxw-id="PPAR919539427" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>UNIV MCMASTER</last-name><address><country>CA</country></address></addressbook></applicant><applicant mxw-id="PPAR919543384" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>MCMASTER UNIVERSITY</last-name></addressbook></applicant><applicant mxw-id="PPAR919015466" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>McMaster University</last-name><iid>101011071</iid><address><street>1280 Main Street West</street><city>Hamilton, ON L8S 4L8</city><country>CA</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919530878" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>BHATIA MICKIE</last-name><address><country>CA</country></address></addressbook></inventor><inventor mxw-id="PPAR919539212" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>BHATIA, MICKIE</last-name></addressbook></inventor><inventor mxw-id="PPAR919015433" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>BHATIA, MICKIE</last-name><address><street>Stem Cell and Cancer Research Institute McMaster University 1280 Main Street West</street><city>Hamilton, Ontario L83 4K1</city><country>CA</country></address></addressbook></inventor><inventor mxw-id="PPAR919513065" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>SACHLOS ELEFTHERIOS</last-name><address><country>CA</country></address></addressbook></inventor><inventor mxw-id="PPAR919542499" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>SACHLOS, ELEFTHERIOS</last-name></addressbook></inventor><inventor mxw-id="PPAR919009074" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>SACHLOS, ELEFTHERIOS</last-name><address><street>Stem Cell and Cancer Research Institute McMaster University 1280 Main Street West</street><city>Hamilton, Ontario L83 4K1</city><country>CA</country></address></addressbook></inventor><inventor mxw-id="PPAR919530834" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>RISUENO RUTH MUNOZ</last-name><address><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR919543427" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>RISUENO, RUTH MUNOZ</last-name></addressbook></inventor><inventor mxw-id="PPAR919009480" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>RISUEÑO, Ruth Muñoz</last-name><address><street>Carrer de Còrsega 80, 4º 4</street><city>E-08026 Barcelona</city><country>ES</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR919012554" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Taylor, Kate Laura</last-name><suffix>et al</suffix><iid>101359809</iid><address><street>Harrison Goddard Foote LLP Saviour House 9 St Saviourgate</street><city>York YO1 8NQ</city><country>GB</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="CA-2012000175-W"><document-id><country>CA</country><doc-number>2012000175</doc-number><kind>W</kind><date>20120228</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012116432-A1"><document-id><country>WO</country><doc-number>2012116432</doc-number><kind>A1</kind><date>20120907</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549916640" load-source="docdb">AL</country><country mxw-id="DS549765435" load-source="docdb">AT</country><country mxw-id="DS549765043" load-source="docdb">BE</country><country mxw-id="DS549776518" load-source="docdb">BG</country><country mxw-id="DS549859777" load-source="docdb">CH</country><country mxw-id="DS549765044" load-source="docdb">CY</country><country mxw-id="DS549765436" load-source="docdb">CZ</country><country mxw-id="DS549916641" load-source="docdb">DE</country><country mxw-id="DS549765057" load-source="docdb">DK</country><country mxw-id="DS549765058" load-source="docdb">EE</country><country mxw-id="DS549846780" load-source="docdb">ES</country><country mxw-id="DS549776519" load-source="docdb">FI</country><country mxw-id="DS549859786" load-source="docdb">FR</country><country mxw-id="DS549916642" load-source="docdb">GB</country><country mxw-id="DS549765059" load-source="docdb">GR</country><country mxw-id="DS549916643" load-source="docdb">HR</country><country mxw-id="DS549765445" load-source="docdb">HU</country><country mxw-id="DS549859787" load-source="docdb">IE</country><country mxw-id="DS549765060" load-source="docdb">IS</country><country mxw-id="DS549776520" load-source="docdb">IT</country><country mxw-id="DS549765073" load-source="docdb">LI</country><country mxw-id="DS549776529" load-source="docdb">LT</country><country mxw-id="DS549846259" load-source="docdb">LU</country><country mxw-id="DS549776530" load-source="docdb">LV</country><country mxw-id="DS549776531" load-source="docdb">MC</country><country mxw-id="DS549846260" load-source="docdb">MK</country><country mxw-id="DS549846261" load-source="docdb">MT</country><country mxw-id="DS549846781" load-source="docdb">NL</country><country mxw-id="DS549844528" load-source="docdb">NO</country><country mxw-id="DS549846786" load-source="docdb">PL</country><country mxw-id="DS549846266" load-source="docdb">PT</country><country mxw-id="DS549859788" load-source="docdb">RO</country><country mxw-id="DS549846267" load-source="docdb">RS</country><country mxw-id="DS549846787" load-source="docdb">SE</country><country mxw-id="DS549765446" load-source="docdb">SI</country><country mxw-id="DS549844529" load-source="docdb">SK</country><country mxw-id="DS549844534" load-source="docdb">SM</country><country mxw-id="DS549776532" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA99837852" ref-ucid="WO-2012116432-A1" lang="EN" load-source="patent-office"><p num="0000">Described are methods of treating a cancer comprising administering to a subject in need thereof an effective amount of a dopamine receptor (DR) antagonist. The DR antagonist may be a phenothiazine derivative, such as thioridazine or chlorpromazine. Optionally, the cancer is acute myeloid leukemia. Also described are methods for identifying subjects with cancer, methods for providing a prognosis for a subjects with cancer and methods for identifying subjects likely to be responsive to therapy with DR receptor antagonists. Methods for identifying cancer stem cells and chemotherapeutic compounds that are DR receptor antagonists as also provided.</p></abstract><abstract mxw-id="PA100333454" ref-ucid="WO-2012116432-A1" lang="EN" source="national office" load-source="docdb"><p>Described are methods of treating a cancer comprising administering to a subject in need thereof an effective amount of a dopamine receptor (DR) antagonist. The DR antagonist may be a phenothiazine derivative, such as thioridazine or chlorpromazine. Optionally, the cancer is acute myeloid leukemia. Also described are methods for identifying subjects with cancer, methods for providing a prognosis for a subjects with cancer and methods for identifying subjects likely to be responsive to therapy with DR receptor antagonists. Methods for identifying cancer stem cells and chemotherapeutic compounds that are DR receptor antagonists as also provided.</p></abstract><abstract mxw-id="PA99837853" ref-ucid="WO-2012116432-A1" lang="FR" load-source="patent-office"><p num="0000">L'invention concerne des méthodes de traitement d'un cancer, comprenant l'administration à un sujet en ayant besoin d'une quantité efficace d'un antagoniste des récepteurs dopaminergiques (DR). L'antagoniste de DR peut être un dérivé de phénothiazine, tel que la thioridazine ou la chlorpromazine. Facultativement, le cancer est une leucémie myéloïde aiguë. L'invention concerne également des procédés d'identification de sujets atteints d'un cancer, des procédés d'obtention d'un pronostic pour des sujets atteints d'un cancer et des procédés d'identification de sujets susceptibles d'être sensibles à une thérapie par des antagonistes des récepteurs DR. L'invention concerne également des procédés d'identification de cellules souches cancéreuses et de composés chimiothérapeutiques qui sont des antagonistes des récepteurs DR.</p></abstract><abstract mxw-id="PA100333455" ref-ucid="WO-2012116432-A1" lang="FR" source="national office" load-source="docdb"><p>L'invention concerne des méthodes de traitement d'un cancer, comprenant l'administration à un sujet en ayant besoin d'une quantité efficace d'un antagoniste des récepteurs dopaminergiques (DR). L'antagoniste de DR peut être un dérivé de phénothiazine, tel que la thioridazine ou la chlorpromazine. Facultativement, le cancer est une leucémie myéloïde aiguë. L'invention concerne également des procédés d'identification de sujets atteints d'un cancer, des procédés d'obtention d'un pronostic pour des sujets atteints d'un cancer et des procédés d'identification de sujets susceptibles d'être sensibles à une thérapie par des antagonistes des récepteurs DR. L'invention concerne également des procédés d'identification de cellules souches cancéreuses et de composés chimiothérapeutiques qui sont des antagonistes des récepteurs DR.</p></abstract><description mxw-id="PDES51233726" ref-ucid="WO-2012116432-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> Treatment of Cancer with Dopamine Receptor Antagonists </p><p id="p0002" num="0002">Related Applications </p><p id="p0003" num="0003">[0001] This application claims priority to US Provisional Patent Application No. 61/447,362 filed on February 28, 2011 , the contents of which are hereby incorporated by reference in their entirety. </p><p id="p0004" num="0004"> Field of the Disclosure </p><p id="p0005" num="0005"> [0002] The disclosure relates to methods for the prognosis or treatment of cancer and particularly to methods for the prognosis or treatment of cancer that target dopamine receptors. </p><p id="p0006" num="0006"> Background of the Disclosure </p><p id="p0007" num="0007"> [0003] Increasing evidence suggests that cancer/tumor development is due to a rare population of cells, termed cancer stem cells (CSCs) (Dick, 2009; Jordan, 2009; Reya et al., 2001 ) that are uniquely able to initiate and sustain disease. In addition, experimental evidence indicates that conventional chemotherapeutics, characterized by their ability to inhibit cell proliferation of cancer cell lines (Shoemaker, 2006) or reduce tumor burden in murine models (Frese and Tuveson, 2007), are ineffective against human CSCs (Guan et al., 2003; Li et al., 2008). This resistance to chemotherapeutics is coupled with indiscriminate cytotoxicity that often affects healthy stem and progenitor cells, leading to dose restriction and necessitating supportive treatment (Smith et al., 2006). Recent examples along these lines include selective induction of apoptosis (Gupta et al., 2009; Raj et al., 2011 ) that remains to be tested in normal SCs and in the human system. Accordingly, the identification of agents that target CSCs alone is now critical to provide truly selective anti-cancer drugs for pre-clinical testing. </p><p id="p0008" num="0008"> [0004] Normal and neoplastic SCs are functionally defined by a tightly controlled equilibrium between self-renewal vs. differentiation potential. In the case of CSCs, this equilibrium shifts towards enhanced self-renewal and survival leading to limited differentiation capacity that eventually allows for 
<!-- EPO <DP n="3"/>-->
 tumor growth. In contrast to direct toxic effects that equally affect normal SCs, an alternative approach to eradicate CSCs is by modification of this equilibrium in favor of differentiation in an effort to exhaust the CSC population. The identification of molecules that selectively target somatic CSCs while sparing healthy SC capacity would therefore be useful for the development of novel diagnostics and therapeutic treatments to selectively target human CSCs. </p><p id="p0009" num="0009"> [0005] Hematological malignancies are types of cancer that affect blood, bone marrow and lymph nodes. Hematological malignancies may derive from either of the two major blood cell lineages: myeloid and lymphoid cell lines. Examples of myeloid malignancies include acute myeloid leukemia and chronic myeloid leukemia. </p><p id="p0010" num="0010"> [0006] While myeloid malignancies are all generally considered to arise from precursors of the myeloid lineage in the bone marrow, they are highly divergent in presentation, pathology and treatment. For example, the 2008 World Health Organization Classification for Myeloproliferative Neoplasms (See Tefferi et al. Cancer, September 1<sup>st</sup>, pp. 3842-3847 (2009); also Vannucchi et al. Advances in Understanding and Management of Myeloproliferative Neoplasms CA Cancer J. Clin. 2009; 59:171-191 , both hereby incorporated by reference), identifies 5 different classification schemes for myeloid neoplasms, and places acute myeloid leukemia (AML) in a separate category from chronic myelogenous leukemia (CML) and other myeloproliferative neoplasms. Furthermore, CML is often characterized as containing the BCR-Abl translocation which is absent in AML. Preferred treatments for leukemias, such as myeloid malignancies, would target leukemic cells without unduly affecting hematopoietic stem cell populations. </p><p id="p0011" num="0011"> [0007] Thioridazine is a dopamine receptor antagonist that belongs to the phenothiazine drug group and is used as an anti-psychotic. It has been in clinical use since 1959, however because of concerns about cardiotoxicity and retinopathy at high doses this drug is not commonly prescribed, and is reserved for patients who have failed to respond to, or have contraindications 
<!-- EPO <DP n="4"/>-->
 for more widely used antipsychotics. Schizophrenic patients receiving dopamine receptor antagonist medication at doses deemed effective for schizophrenia have been reported to have a reduced incidence of rectum, colon, and prostate cancer compared to the general population. </p><p id="p0012" num="0012">[0008] There is a need for novel methods for the treatment and prognosis of cancers and in particular for novel methods for the treatment and prognosis of acute myeloid leukemia. </p><p id="p0013" num="0013"> Summary of the Disclosure </p><p id="p0014" num="0014"> [0009] It has surprisingly been determined that dopamine receptor antagonists such as thioridazine or chlorpromazine are cytotoxic to cancer cells and in particular acute myeloid leukemia (AML). Furthermore, dopamine receptors antagonists at concentrations toxic to cancer cells have been found to have a relatively limited effect on normal stem cells such as hematopoietic stem cells. It has also been determined that dopamine receptors are expressed in AML cell lines and in primary AML cells, but show relatively less expression in cell lines enriched for normal hematopoietic stem cells. In addition, the expression of dopamine receptors in AML cells is shown to correlate with that of the monoblastic marker CD 14. Dopamine receptor antagonists such as thioridazine are cytotoxic to AML cells that express CD14. </p><p id="p0015" num="0015"> [0010] Accordingly, in one aspect there is provided a method of treating a cancer or precancerous disorder in a subject comprising administering to the subject in need thereof a dopamine receptor (DR) antagonist. In a similar aspect, the present disclosure describes the use of a dopamine receptor antagonist for the treatment of cancer or a precancerous disorder. In one embodiment, the cancer or precancerous disorder is a myeloproliferative disease or leukemia. In one embodiment, the cancer is acute myeloid leukemia (AML). In one embodiment, the DR antagonist preferentially induces the differentiation of cancer stem cells relative to hematopoietic or normal stem cells. 
<!-- EPO <DP n="5"/>-->
 [0011] In one embodiment, the dopamine receptor antagonist is a phenothiazine derivative such as thioridazine or chlorpromazine. Optionally the dopamine receptor antagonist is a multi-receptor antagonist that antagonizes more than one dopamine receptor. In one embodiment, the dopamine receptor antagonist is a D<sub>2</sub> family dopamine receptor antagonist. In one embodiment, the DR antagonist is a compound selected from those listed in Table 1. </p><p id="p0016" num="0016"> [0012] In another aspect there is provided a method for reducing the proliferation of a cancer cell comprising contacting the cancer cell with a dopamine receptor antagonist. In a similar aspect there is provided the use of a dopamine receptor antagonist for reducing the proliferation of a cancer cell. In one embodiment, contacting the cell with a dopamine receptor antagonist induces cell death or differentiation of a cancer cell or precancerous cell. In one embodiment, the cancer cell is a cancer stem cell and contacting the cancer stem cell with a dopamine receptor antagonist induces differentiation of the cancer stem cell. The cell may be in vivo or in vitro. In one embodiment, the precancerous cell is a myeloproliferative cell. Optionally, the cancer cell is a leukemic cell, such as an acute myeloid leukemia (AML) cell or a monocytic leukemic cell. In one embodiment, the cell is CD14 positive. In one embodiment, the dopamine receptor antagonist is a phenothiazine derivative such as thioridazine. In one embodiment, the dopamine antagonist is a compound selected from those listed in Table 1. </p><p id="p0017" num="0017"> [0013] In another aspect there is provided a method of identifying a subject with cancer suitable for treatment with a dopamine receptor antagonist. In one embodiment, the method includes determining the expression of one or more dopamine receptors in a sample of cancer cells from the subject. In one embodiment, subjects with cancer cells that express one or more dopamine receptors are identified as suitable for treatment with dopamine receptor antagonists. In one embodiment, the cancer is leukemia and the cancer cells are leukemic cells. In one embodiment, the leukemia is acute myeloid leukemia or monocytic leukemia. In one embodiment, the 
<!-- EPO <DP n="6"/>-->
 cancer is breast cancer. In one embodiment, the method of identifying a subject with cancer comprises testing the sample for the expression of CD14. </p><p id="p0018" num="0018"> [0014] In one aspect, there is provided a method for determining a prognosis for a subject with cancer, comprising determining the expression level of one or more dopamine receptor biomarkers in a sample from the subject and comparing the level of expression of the one or more biomarkers to a control. Optionally, the method provided herein include providing or obtaining a sample of cancer cells from the subject. In one embodiment, increased expression of one or more biomarkers compared to the control indicates a more severe form of cancer. In one embodiment, the dopamine receptor biomarkers are DR3 and/or DR5. In one embodiment, the cancer is leukemia or breast cancer and the sample comprises leukemic cells or breast cancer cells. In one embodiment, the leukemia is acute myeloid leukemia or monocytic leukemia. </p><p id="p0019" num="0019">[0015] Also provided are methods for identifying a subject with leukemia. In one embodiment, the methods include determining the expression level of one or more dopamine receptors in a sample from the subject and comparing the level of expression of the one or more dopamine receptors to a control. Optionally, sample comprises white blood cells and/or the method further comprises providing a sample comprising white blood cells from the subject. In one embodiment, increased expression levels of one or more dopamine receptors compared to a control is indicative of a subject with leukemia, such as acute myeloid leukemia, or monocytic leukemia. In one embodiment, the method further comprises testing for CD14. </p><p id="p0020" num="0020">[0016] Also provided are methods for screening compounds for anticancer activity comprising identifying compounds that are dopamine receptor antagonists. In one embodiment, the anti-cancer activity is reduced proliferation of AML cells or monocytic cells. Optionally, the methods include identifying compounds that preferentially induce the differentiation of cancer stem cells relative to hematopoietic or normal stem cells. 
<!-- EPO <DP n="7"/>-->
 [0017] In one aspect, there is provided methods for identifying a cancer stem cell from a population of cells. In one embodiment, the method comprises determining whether a cell expresses one or more biomarkers selected from dopamine receptor (DR) 1 , DR2, DR3, DR4 and DR5. In one embodiment, the expression of dopamine receptor (DR) 1 , DR2, DR3, DR4 and/or DR5 is indicative that the cell is a cancer stem cell. </p><p id="p0021" num="0021"> [0018] In one embodiment, the population of cells comprises cells isolated from a mammal or cells in culture such as cell culture. In one embodiment, the population of cells comprises pluripotent stem cells. In one embodiment, the population of cells comprises cancer cells such as hematological cancer cells or pre-cancerous cells. Optionally, the method includes testing the cell for the expression of polynucleotides or polypeptides that code for DR1 , DR2, DR3, DR4 or DR5. In one embodiment, a cell that expresses DR1 , DR2, DR3, DR4 and DR5 is identified as a cancer stem cell. In some embodiments, the methods described herein also include isolating cancer stem cells from a population of cells. For example, cells that are identified as cancer stem cells can be isolated from a population of cells or other material using methods known in the art such as flow cytometry, fluorescence activated cell sorting, panning, affinity column separation, or magnetic selection. In one embodiment, cancer stem cells are isolated using antibodies to one or more of DR1 , DR2, DR3, DR4 and DR5. </p><p id="p0022" num="0022"> [0019] Other features and advantages of the present disclosure will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the disclosure are given by way of illustration only, since various changes and modifications within the spirit and scope of the disclosure will become apparent to those skilled in the art from this detailed description. </p><p id="p0023" num="0023"> Brief Description of the Drawings </p><p id="p0024" num="0024">[0020] One or more embodiments of the disclosure will now be described in relation to the drawings in which: 
<!-- EPO <DP n="8"/>-->
 ( </p><p id="p0025" num="0025"> [0021] Figure 1 shows thioridazine at 10 μΜ is cytotoxic to leukemic cell lines HL-60, MV4-1 1 and OCI3. </p><p id="p0026" num="0026"> [0022] Figure 2 shows that thioridazine 10μΜ has limited affects on the colony forming potential of normal HSCs (2A) while significantly reducing AML blast forming potential. </p><p id="p0027" num="0027"> [0023] Figure 3 shows cell pellets of CFU colonies generated from normal HSC and AML treated with Thioridazine. </p><p id="p0028" num="0028"> [0024] Figure 4 shows that both 10 μΜ chlorpromazine and 10 μΜ thioridazine is cytotoxic to leukemic cell lines HL-60, MV4-11 and OCI3. </p><p id="p0029" num="0029">[0025] Figure 5 shows the expression of dopamine receptors DR1 , DR2, DR3, DR4 and DR5. DR expression was observed in AML cell lines, some primary AML and mononuclear cells (MNC) but not in HSC enriched cells (CB lin(-)). </p><p id="p0030" num="0030"> [0026] Figure 6 shows that multiple DR antagonists are cytotoxic to AML cell lines. SKF = (R)-(+)-SKF-38393 hydrochloride; 70H = R(+)-7- Hydroxy-DPAT hydrobromide; GR = GR 103691 ; SCH = R(+)-SCH-23390 hydrochloride; CLOZ = Clozapine; CHL = Chlorpromazine hydrochloride; THIO = Thioridazine. </p><p id="p0031" num="0031"> [0027] Figure 7 shows FACS data showing that dopamine receptors are expressed in the population of CD14+ cells in primary AML. </p><p id="p0032" num="0032"> [0028] Figure 8 shows that thioridazine selectively targets and reduces the normalized frequency of CD14+ cells in primary AML. </p><p id="p0033" num="0033"> [0029] Figure 9 shows the identification of mefloquine and thioridazine using chemical screening for compounds that differentiate neoplastic hPSC. (A) Schematic of screening strategy. (B) XY-scatter plot of percent residual activity (%RA) of GFP and Hoechst signals of the 590 compound screen. Region outlined demonstrates loss of pluripotency (LOP) as defined by reduced GFP and Hoechst. Each point n=3, mean+/-SD (C) Summary of responses seen with 590 compounds. (D) Chemical structure of candidate 
<!-- EPO <DP n="9"/>-->
 compounds; thioridazine, azathioprine and mefloquine. (E) Representative GFP, Hoechst and merged microscopic images of v1H9-Oct4-GFP cells treated with candidate compounds at 10μΜ . (F) Histogram of GFP intensity of these images. (G) Dose response curves of v1 H9-Oct4-GFP treated with candidate compounds and calculation of EC<sub>50</sub>. Each point n=3; mean+/- SEM. </p><p id="p0034" num="0034"> [0030] Figure 10 shows the effect of salinomycin, mefloquine and thioridazine on normal and neoplastic populations. (A-B) Flow cytometry analysis of frequency of Oct4+ cells in (A) H9 and (B) v1 H9-Oct4-GFP cells treated with salinomycin (SAL), mefloquine (MQ) and thioridazine (THIO) at 10<sup>"7</sup> - 10<sup>6</sup>M. Each bar n=3; mean+/-SD. Values are normalized to DMSO-treated control samples; (-) DMSO mean, (-) mean minus one SD, (-) level of %Oct4+ in BMP4 treated samples. (C) Ratio of normalized %Oct4+ cells in H9 per v1 H9-Oct-GFP with same compound at the same concentration. Percent of neoplastic hPSC staining positive for (D) p53 and (E) p21 following 24h treatment with 10μΜ etoposide, 10μΜ thioridazine (THIO), BMP4 and DMSO-treated (CTRL) controls. Each bar n=3; mean+/-SD. Representative images of etoposide and thioridazine treated cells included. Arrows show p53+ and p21 + in etoposide-treated cells versus thioridazine-treated cells. (F) Differentiation-associated genes with &gt; 2 fold increase following thioridazine treatment of neoplastic hPSC. Genes divided into respective lineages, endoderm (ENDO), mesoderm (MESO), germ cell (GERM), neural (NEURO) and trophoblast (TROPH). Each bar represents the mean of two separate experiments. (G-K) Hematopoietic multilineage and clonogenic potential in response to compound treatment detected using methycellulose assays. Representative colony forming unit (CFU) pellets of (G) hematopoietic stem and progenitor cells (HSPC) versus (H) AML blast CFUs pellets following compound treatment. (I-J) Quantification of respective CFUs and blast-CFUs generated from (I) HSPC and (J) AML blast cells following compound treatment. Values were normalized to DMSO-treated control samples; (-) DMSO 
<!-- EPO <DP n="10"/>-->
 mean, (--) mean minus one SEM. Each HSPC bar n=7 individual samples, mean+ASE . Each AML bar at least n=5 individual patient samples, mean+/-SEM. (K) Ratio of normalized HSPC CFUs per AML blast CFUs with same compound at the same concentration. (L) Frequency of normalized CD1 1 b granulocytic cells in cultured patient AML cells treated with thioridazine 10μΜ (THIO 10μΜ) or DMSO vehicle (CTRL) for up to 96 hours. Each bar n=3, mean+/-SD. (<sup>*</sup>) p&lt;0.05, (**) p&lt;0.01 , (**<sup>*</sup>) p&lt;0.001 , (*<sup>*</sup>**) p&lt;0.0001 . </p><p id="p0035" num="0035"> [0031] Figure 1 1 shows the effect of salinomycin, mefloquine and thioridazine on fibroblast-derived iPSC and HSPC. (A) Flow cytometry analysis of frequency of Oct4+ cells in fibroblast-derived iPSC (Fib- iPS) treated with salinomycin (SAL), mefloquine (MQ) and thioridazine (THIO) at 10<sup>"7</sup> - 10<sup>"6</sup>M. Each bar n=3; mean+/-SD. Values are normalized to DMSO-treated control samples; (-) DMSO mean, (-) mean minus one SD, (-) level of %Oct4+ in BMP4 treated samples. (B) Extended dose response of compounds on neoplastic hPSC. Each point mean+/- SEM, (C) Hematopoietic lineage potential of CBlin- treated with thioridazine. Colony forming units (CFUs) of erythoblast (CFU-E), macrophage (CFU-M) and granulocyte (CFU-G) colonies generated in methylcellulose assays. (D) Composition of CFU generated from CBlin- treated with salinomycin, mefloquine and thioridazine. Percent composition of CFUs generated with salinomycin (SAL), mefloquine (MQ) and thioridazine (THIO) treatment at 0.1 μΜ, 1 μΜ and 10μΜ. (*) p&lt;0.05, (**) p&lt;0.01 </p><p id="p0036" num="0036"> [0032] Figure 12 shows thioridazine's effect on HSC and LSC engraftment. (A) Frequency of human CD45+ cells in the bone marrow following HSPC treatment with thioridazine 10μΜ (THIO 10μΜ) or mefloquine 10μΜ (MQ 10μΜ). Values normalized to DMSO-treated HSPC control (CTRL) samples. Total of two HSPC samples evaluated. Mean+/- SEM. (B) Representative flow cytometry plots of side scatter (SSC) versus myeloid (CD33) or lymphoid (CD19) markers within the hCD45+ population. 12(C) Frequency of CD45+ CD33+ AML blast cells in the bone marrow 
<!-- EPO <DP n="11"/>-->
 (BM) following treatment of AML with thioridazine 10μΜ (THIO 10μΜ) or mefloquine 10μΜ (MQ 10μΜ). Values normalized to DMSO-treated AML control (CTRL) samples. Total of two AML patient samples evaluated. (D) Representative flow plots of CD33 vs CD45 in DMSO-treated control (CTRL) populations versus thioridazine treated (THIO 10μΜ). (E) Ratio of normalized percent hCD45 HSPC engraftment per normalized percent CD45 CD33 AML blast engraftment. (*) p&lt;0.05 </p><p id="p0037" num="0037"> [0033] Figure 13 shows in vivo response to drug treatment. (A) The normalized frequency of human CD45+ cells in the bone marrow following HSPC treatment with salinomycin 1 μΜ (SAL 1 μΜ) relative to DMSO- treated (CTRL) samples. Total of two HSPC samples evaluated. Mean+/- SEM. (<sup>*</sup>***) pO.0001 (B) Thioridazine's effect on HSC and LSC splenic engraftment. (B, top) Frequency of human CD45+ cells in the spleen following HSPC treatment with thioridazine 10μΜ (THIO 10μΜ). Values normalized to DMSO-treated HSPC control (CTRL) samples. Total of two HSPC samples evaluated. Mean+/- SEM. (B, bottom) CD45+ CD33+ blast cells in the spleen following thioridazine 10μΜ (THIO 10μΜ) treatment of AML. Values normalized to DMSO-treated AML control (CTRL) samples. Total of two AML patient samples evaluated. (C) Thioridazine's effect on erythrocytic and megakaryocytic regeneration. Composition of human blood cells detected in the xenotransplant BM injected with HSPC treated with thioridazine 10μΜ (THIO 10μΜ ) or with DMSO (CTRL). Red blood cells (RBC) are defined by glycophorin A positivity and platelets by CD41 a. (D) Confirmation of myeloid leukemic engraftment of xenotransplants with AML. Flow cytometry of side scatter versus CD19, a marker of lymphoid cells. Inset number represents mean+/-SEM. (E-F) Thioridazine's effect on HSC and LSC in vivo self-renewal. Engraftment levels of (E) hCD45+ cells or (F) hCD45+CD33+ in BM of secondary xenotransplants receiving equal number of hCD45 cells explanted from (E) primary CBlin- or (F) primary AML transplants treated with thioridazine (THIO 10μΜ) or DMSO control (CTRL). Each bar n=3 mice, mean+/-SEM. 
<!-- EPO <DP n="12"/>-->
 [0034] Figure 14 shows dopamine receptors expressed on neoplastic stem cells. (A-B) Flow cytometry of (A) normal H9 and (B) neoplastic v1 H9-Oct4-GFP cells stained with SSEA3 and all five dopamine receptor (DR) subtypes. DR expression in the SSEA3+ fraction is shown. (C) Flow cytometry of lineage-depleted cord blood (HSPC) stained with CD34, CD38 and all five DR subtypes. DR expression is presented in the gated populations. (D) Flow cytometry of 13 AML patient samples stained for all five DRs along with associated FAB classification. (E) Co-localization of DRD5 in triple-negative (ER-, PR- and HER2-) primary human breast tumor stained with CD44 and CD24. (F) The frequency of triple-negative breast CSC (CD44+CD24-/<sup>10</sup>) within the DRD3 and DRD5 population. Each bar composed of 3 primary triple-negative breast tumors, mean +/-SEM. (G-H) Frequency of AML blast cells (CD33+CD45+) from patient samples which are also positive for (G) DRD3 and (H) DRD5. A total of 8 AML patient samples were assessed for leukemic-initiation potential in xenotransplantation recipients. Leukemic-initiating was defined as human engraftment &gt;0.1 % of CD33+ hCD45+ in mouse bone marrow. Four leukemic-initiating AML samples were assayed in 22 mice while 4 non- initiating AML samples were assayed in 17 mice. Total n=8 AML samples, mean+/-SEM. </p><p id="p0038" num="0038"> [0035] Figure 15 (A-B) Flow cytometry SSEA3+ fraction in (A) fibroblast-derived hiPSC and (B) umbilical cord blood-derived hiPSC stained for all five dopamine receptors. (C) Dopamine receptors expression of human blood populations. Flow cytometry of cord blood mononuclear cells stained for (C) erythroid (glycophorin A), (C) megakaryocytes (CD41 a); (D) T-cells (CD3), (D) B-cells (CD19); (E) monocytes (CD14) and (E) granulocytes (CD15). Staining for all five DRs in the gated populations are shown as histograms. (F) Summary of DR localization in the blood populations. (G) Flow cytometry of AML patient showing DR in gated populations. (H) Dopamine receptor expression in triple-negative human breast tumors. Breast CSC are defined as CD44+ CD24-/'° (Al-Hajj et al., 
<!-- EPO <DP n="13"/>-->
 2003). Co-localization of each DR within the CD44 and CD24 population is shown for three triple-negative (ER-, PR- and HER2-) breast tumors. </p><p id="p0039" num="0039"> [0036] Figure 16 shows that thioridazine inhibits dopamine receptor signalling in AML. (A) DR expression of AML-OCI2 and AML-OCI3 cell lines. (B) Cell counts of AML-OCI2 and AML-OCI3 cells treated with three DR antagonist drugs. Values are normalized to DMSO-treated control samples. Each bar n=3; mean+/-SD. (C-D) Viable cell counts (7AAD-, Hoechst+) of same cell lines treated with (C) 70H-DPAT, a DR D2-family agonist, or (D) SKF38393, a DR D1 -family agonist, in serum-free conditions. Values are normalized to DMSO-treated control samples. Each bar n=3; mean+/-SD. </p><p id="p0040" num="0040"> Detailed Description </p><p id="p0041" num="0041">I. Definitions </p><p id="p0042" num="0042"> [0037] As used herein, the term "cancer" refers to one of a group of diseases caused by the uncontrolled, abnormal growth of cells that can spread to adjoining tissues or other parts of the body. Cancer cells can form a solid tumor, in which the cancer cells are massed together, or exist as dispersed cells, as in leukemia. </p><p id="p0043" num="0043"> [0038] The term "cancer cell" as used herein refers a cell characterized by uncontrolled, abnormal growth and the ability to invade another tissue or a cell derived from such a cell. Cancer cell includes, for example, a primary cancer cell obtained from a patient with cancer or cell line derived from such a cell. Similarly, a "hematological cancer cell" refers to a cancer cell deriving from a blood cell or bone marrow cell. Examples of cancer cells include, but are not limited to, cancer stem cells, breast cancer cells, rectum cancer cells, colon cancer cells, prostate cancer cells and hematological cancer cells such as myelomas, leukemic cells or lymphoma cells. </p><p id="p0044" num="0044"> [0039] As used herein the term "cancer stem cell" refers to a cell that is capable of self-renewal and differentiating into the lineages of cancer cells that comprise a tumor or hematological malignancy. Cancer stem cells are uniquely able to initiate and sustain the disease. 
<!-- EPO <DP n="14"/>-->
 [0040] The term "precancerous disorder" as used herein refers to one of a group of hyperproliferative disorders that can develop into cancer, including for example precancerous blood disorders, such as myeloproliferative disease or myelodysplastic syndrome which is a premalignant condition that is related to and/or can develop into acute myeloid leukemia (AML). </p><p id="p0045" num="0045"> [0041] The term "precancerous cell" as used herein refers to a cell characterized by uncontrolled, abnormal growth or a cell derived from such a cell. The term "precancerous cell" includes, for example, a primary precancerous cell obtained from a patient with precancerous disorder or cell line derived from such a cell or a cancer stem cell. Similarly, a "hematological precancerous cell" refers to a precancerous cell deriving from a blood cell or bone marrow cell. In one embodiment, the hematological precancerous cell is a myeloproliferative cell. </p><p id="p0046" num="0046">[0042] The term "leukemia" as used herein refers to any disease involving the progressive proliferation of abnormal leukocytes found in hemopoietic tissues, other organs and usually in the blood in increased numbers. "Leukemic cells" refers to leukocytes characterized by an increased abnormal proliferation of cells. Leukemic cells may be obtained from a subject diagnosed with leukemia. </p><p id="p0047" num="0047"> [0043] The term "acute myeloid leukemia" or "acute myelogenous leukemia" ("AML") refers to a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. Pre-leukemic conditions such as myelodysplastic or myeloproliferative syndromes may also develop into AML. </p><p id="p0048" num="0048"> [0044] As used herein, the term "monocytic leukemia" refers to a subtype of leukemia characterized by the expression of CD14, and includes Acute Monocytic Leukemia, which is a subtype of acute myeloid leukemia. In one embodiment, a subject is identified as having acute monocytic leukemia if 
<!-- EPO <DP n="15"/>-->
 they have greater than 20% blasts in the bone marrow, and of these, greater than 80% are of the monocytic lineage. </p><p id="p0049" num="0049"> [0045] The term "dopamine receptor antagonist" refers to a compound that produces any detectable or measurable reduction in the function or activity of one or more dopamine receptors. In one embodiment, the dopamine receptors (DR) are selected from DR1 , DR2, DR3, DR4 and DR5. Dopamine receptor antagonists may be selective for one or multiple dopamine receptors, i.e. a "multi-receptor antagonist". Examples of multi-receptor dopamine antagonists include thioridazine and chlorpromazine. Dopamine receptors are commonly grouped in Drfamily dopamine receptors (DR1 and DR5) and D<sub>2</sub>-family dopamine receptors (DR2, DR3 and DR4). In one embodiment, the dopamine receptor antagonist is a compound selected from those listed in Table 1. </p><p id="p0050" num="0050"> Table 1 : Dopamine antagonists suitable for use in the methods described herein. </p><p id="p0051" num="0051"> Dopamine Receptor Antagonist Mechanism of Action </p><p id="p0052" num="0052"> Acetopromazine maleate salt Dopaminergic antagonist </p><p id="p0053" num="0053"> Amisulpride D2 and D3 receptor antagonist </p><p id="p0054" num="0054"> Amoxapine Dopamine-reuptake inhibitor </p><p id="p0055" num="0055"> Azaperone Dopaminergic receptor antagonist </p><p id="p0056" num="0056"> Benperidol Dopamine antagonist </p><p id="p0057" num="0057"> Benzo[a]phenanthridine-10,11-diol, D1 ligand </p><p id="p0058" num="0058">5,6,6a,7,8,12b-hexahydro-, trans- [CAS] </p><p id="p0059" num="0059"> Bromopride Dopamine antagonist </p><p id="p0060" num="0060"> Bromperidol Dopamine antagonist </p><p id="p0061" num="0061"> Chlorpromazine hydrochloride D2 antagonist, selective D1 , D3, D4 &amp; D5</p><p id="p0062" num="0062">Chlorprothixene hydrochloride D2 dopamine receptor antagonist </p><p id="p0063" num="0063"> Clomipramine hydrochloride chlorpromazine derivative </p><p id="p0064" num="0064"> Disulfiram Dopamine beta-hydroxylase inhibitor </p><p id="p0065" num="0065"> DO 897/99 D3 antagonist </p><p id="p0066" num="0066"> Domperidone Dopamine Antagonists </p><p id="p0067" num="0067"> DROPERIDOL D2 (dopamine receptor) antagonist </p><p id="p0068" num="0068"> Ethopropazine hydrochloride Thioridazine derivative </p><p id="p0069" num="0069"> Fluperlapine D2 (dopamine receptor) antagonist </p><p id="p0070" num="0070"> Fluphenazine dihydrochloride Dopamine antagonist D1&amp;D2 antagonist</p><p id="p0071" num="0071">GBR 12909 dihydrochloride Dopamine reuptake inhibitor </p><p id="p0072" num="0072"> Haloperidol Dopamine antagonist D2, non-selective antagonist 
<!-- EPO <DP n="16"/>-->
 Dopamine Receptor Antagonist Mechanism of Action </p><p id="p0073" num="0073"> Hydrastinine hydrochloride Dopamine receptor blocker </p><p id="p0074" num="0074"> Indatraline potent D antagonist </p><p id="p0075" num="0075"> Itopride Dopamine D2 receptors and ACE inhibition</p><p id="p0076" num="0076">LEVOSULPIRIDE D2, D3, &amp; D4 antagonist </p><p id="p0077" num="0077"> Loxapine succinate Dopamine antagonist/ D2, D4 </p><p id="p0078" num="0078"> Mesoridazine D2 antagonist </p><p id="p0079" num="0079"> Mesoridazine besylate D antagonist </p><p id="p0080" num="0080"> Methotrimeprazine maleat salt Thioridazine derivative </p><p id="p0081" num="0081"> Metixene hydrochloride Thioridazine derivative </p><p id="p0082" num="0082"> Molindone hydrochloride Dopamine receptor antagonist </p><p id="p0083" num="0083"> Nafadotride D3 antagonist </p><p id="p0084" num="0084"> Nomifensine maleate Dopamine uptake inhibitor </p><p id="p0085" num="0085"> OLANZAPINE D1&amp;D2 antagonist </p><p id="p0086" num="0086"> PEROSPIRONE HCI D2&amp;D4 antagonist </p><p id="p0087" num="0087"> Perphenazine D1 &amp; D2 antagonist </p><p id="p0088" num="0088"> PHENOTHIAZINE Thioridazine derivative </p><p id="p0089" num="0089"> Pimozide Dopamine antagonist </p><p id="p0090" num="0090"> Piperacetazine Thioridazine derivative </p><p id="p0091" num="0091"> Prochlorperazine Thioridazine derivative </p><p id="p0092" num="0092"> Prochlorperazine dimaleate Dopamine antagonist </p><p id="p0093" num="0093"> Promazine hydrochloride Dopamine receptor antagonist </p><p id="p0094" num="0094"> Promethazine hydrochloride Thioridazine derivative </p><p id="p0095" num="0095"> Quetiapine dopamine and serotonin receptors antagonist</p><p id="p0096" num="0096">QUETIAPINE HEMIFUMARATE D2 antagonist </p><p id="p0097" num="0097"> R(+)-SCH-23390 hydrochloride D1 antagonist </p><p id="p0098" num="0098"> Raclopride D2 antagonist </p><p id="p0099" num="0099"> Remoxipride Hydrochloride Dopaminergic antagonist </p><p id="p0100" num="0100"> RISPERIDONE D1 &amp; D2 antagonist </p><p id="p0101" num="0101"> S(-)Eticlopride hydrochloride Dopamine receptor antagonist </p><p id="p0102" num="0102"> Sertindole Dopamine D2/Serotonin 5-HT2 receptor antagonist </p><p id="p0103" num="0103"> SKF 83566 D1 antagonist </p><p id="p0104" num="0104"> Spiperone D2 antagonist </p><p id="p0105" num="0105"> Sulpiride D2 antagonist </p><p id="p0106" num="0106"> Sulpiride D2 &amp; D3 antagonist </p><p id="p0107" num="0107"> Thiethylperazine malate Thioridazine derivative </p><p id="p0108" num="0108"> Thioproperazine dimesylate D1 &amp; D2 antagonist </p><p id="p0109" num="0109"> Thioridazine hydrochloride Thioridazine derivative </p><p id="p0110" num="0110"> TRIFLUOPERAZINE D2 antagonist </p><p id="p0111" num="0111"> Triflupromazine hydrochloride D1 &amp; D2 antagonist </p><p id="p0112" num="0112"> Trimeprazine tartrate Thioridazine derivative </p><p id="p0113" num="0113"> Trimethobenzamide hydrochloride D2 antagonist </p><p id="p0114" num="0114"> Ziprasidone Hydrochloride Dopamine D2/serotonin 5-HT2 antagonist</p><p id="p0115" num="0115">Zotepine Dopamine D2/serotonin 5-HT2 antagonist</p><p id="p0116" num="0116">Table 1 (Continued) 
<!-- EPO <DP n="17"/>-->
 [0046] As used herein, the term "phenothiazine" or "phenothiazine derivative" refers to a compound that is derived from or contains a phenothiazine moiety or backbone. Phenothiazine has the formula S(C<sub>6</sub>H<sub>4</sub>)<sub>2</sub>NH and phenothiazine derivatives comprise one or more substitutions or additions to phenothiazine. For example, some phenothiazine derivatives have a three-ring structure in which two benzene rings are linked by a nitrogen and a sulfur. Examples of phenothiazine derivatives include thioridazine, chlorpromazine, levomepromazine, mesoridazine, fluphenazine, perphenazine, prochlorperazine, and trifluoperazine. Additional examples of phenothiazine derivatives for use in the methods of the present disclosure are set out in Table 1. In one embodiment, thioridazine has the lUPAC name 10- {2-[(/?S)-1-Methylpiperidin-2-yl]ethyl}-2-methylsulfanylphenothiazine. </p><p id="p0117" num="0117">Optionally, one or more racemic forms of a phenothiazine derivative such as thioridazine are used in the methods described herein. </p><p id="p0118" num="0118">[0047] As used herein, "reducing the proliferation of a cancer cell" refers to a reduction in the number of cells that arise from a cancer cell as a result of cell growth or cell division and includes cell death or differentiation of a cancer stem cell. The term "cell death" as used herein includes all forms of cell death including necrosis and apoptosis. As used herein "differentiation of a cancer stem cell" refers to the process by which a cancer stem cell loses the capacity to self-renew and cause the lineages of cancer cells that comprise a tumor or hematological malignancy. </p><p id="p0119" num="0119"> [0048] The term "determining a prognosis" refers to a prediction of the likely progress and/or outcome of an illness, which optionally includes defined outcomes (such as recovery, symptoms, characteristics, duration, recurrence, complications, deaths, and/or survival rates). </p><p id="p0120" num="0120"> [0049] As used herein the term "control" refers to a comparative sample or a pre-determined value. In one embodiment, "control" refers to a level of expression of a biomarker as described herein. In one embodiment, the control is representative of normal, disease-free cell, tissue, or blood. In one embodiment, the control is representative of subjects with cancer for whom 
<!-- EPO <DP n="18"/>-->
 the clinical outcome or severity of the disease is known. For example, in one embodiment the "control" is representative of subjects who have survived for at least 5 years after a diagnosis with AML. In one embodiment, the "control" is representative of subjects with cancer who have a particular stage of grade of the disease. In one embodiment, the "control" is representative of stem cells that are not cancer stem cells. </p><p id="p0121" num="0121"> [0050] As used herein, the phrase "effective amount" or "therapeutically effective amount" means an amount effective, at dosages and for periods of time necessary to achieve the desired result. For example in the context or treating a cancer such as AML, an effective amount is an amount that for example induces remission, reduces tumor burden, and/or prevents tumor spread or growth of leukemic cells compared to the response obtained without administration of the compound. Effective amounts may vary according to factors such as the disease state, age, sex and weight of the animal. The amount of a given compound that will correspond to such an amount will vary depending upon various factors, such as the given drug or compound, the pharmaceutical formulation, the route of administration, the type of disease or disorder, the identity of the subject or host being treated, and the like, but can nevertheless be routinely determined by one skilled in the art. </p><p id="p0122" num="0122">[0051] The term "pharmaceutically acceptable" means compatible with the treatment of animals, in particular, humans. </p><p id="p0123" num="0123"> [0052] The term "subject" as used herein includes all members of the animal kingdom including mammals, and suitably refers to humans. Optionally, the term "subject" includes mammals that have been diagnosed with cancer or are in remission. </p><p id="p0124" num="0124"> [0053] The term "treating" or "treatment" as used herein and as is well understood in the art, means an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e. not worsening) state of disease (e.g. maintaining a patient in remission), 
<!-- EPO <DP n="19"/>-->
 preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission (whether partial or total), whether detectable or undetectable. "Treating" and "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. "Treating" and "treatment" as used herein also include prophylactic treatment. In one embodiment, treatment methods comprise administering to a subject a therapeutically effective amount of a dopamine receptor antagonist as described herein and optionally consists of a single administration, or alternatively comprises a series of administrations. </p><p id="p0125" num="0125"> II. Methods and Uses </p><p id="p0126" num="0126"> [0054] It has surprisingly been found that dopamine receptor (DR) antagonists are cytotoxic to AML lines and primary AMLs while being much less toxic to normal hematopoietic stem cells. As shown in Examples 2 and 10, the DR antagonist thioridazine significantly reduced leukemic stem cell (LSC) function while preserving normal hematopoietic stem cell capacity. </p><p id="p0127" num="0127"> [0055] Accordingly, in one embodiment there is provided a method of treating a cancer or precancerous disorder in a subject comprising administering to the subject in need thereof a dopamine receptor antagonist. Also provided is a use of a dopamine receptor antagonist for the treatment of cancer or a precancerous disorder. In one embodiment, the methods or uses described herein are useful to treat a precancerous disorder, such as a myeloproliferative disease. In one embodiment, the cancer is leukemia such as acute myeloid leukemia (AML), or monocytic leukemia. The methods and uses described herein are particularly useful for the treatment of cancer cells that express dopamine receptors. In one embodiment, the methods and uses described herein are useful for the treatment of cancer cells that express the monocytic marker CD14. In one embodiment, the dopamine receptor antagonist preferentially induces the differentiation of cancer stem cells in the subject relative to hematopoietic or normal stem cells. In one embodiment, the 
<!-- EPO <DP n="20"/>-->
 cancer stem cells are leukemic cancer stem cells. In one embodiment, the subject has AML and the cancer stem cells are AML cancer stem cells. </p><p id="p0128" num="0128"> [0056] In one embodiment, the dopamine receptor antagonists are antagonists for one or more of dopamine receptors (DR) such as DR1 , DR2, DR3, DR4, and DR5. Optionally the DR antagonist is a multi-receptor antagonist, or is specific for a single dopamine receptor subtype. In one embodiment, the DR antagonist is a phenothiazine derivative such as thioridazine, or chlorpromazine. In one embodiment, the DR antagonist is selected from the compounds listed in Table 1. A person of skill in the art would readily be able to identify additional dopamine receptor antagonists that are useful for the treatment of cancer as described herein. </p><p id="p0129" num="0129"> [0057] In one embodiment, the methods or uses described herein involve a phenothiazine derivative such as thioridazine or chlorpromazine. A person skilled in the art would readily be able to identify additional phenothiazine derivatives that are dopamine receptor antagonists and useful for the treatment of cancer as described herein. In one embodiment, the phenothiazine derivatives have a differential toxicity for cancer cells, such as leukemic cells, compared to normal stem cells or hematopoietic stem cells. </p><p id="p0130" num="0130"> [0058] In one embodiment, the dopamine receptor antagonists and/or phenothiazine derivatives are prepared for administration to a subject in need thereof as known in the art. Conventional procedures and ingredients for the selection and preparation of suitable formulations are described, for example, in Remington's Pharmaceutical Sciences (2003 - 20th edition) and in The United States Pharmacopeia: The National Formulary (USP 24 NF19) published in 1999. </p><p id="p0131" num="0131"> [0059] In one embodiment, there is also provided a method for reducing the proliferation of a cancer cell or cells comprising contacting the cell with a dopamine receptor antagonist. In a similar embodiment there is provided a use of a dopamine receptor antagonist for reducing the proliferation of a cancer cell or cells. In one embodiment, the cancer cell is a cancer stem cell. In one embodiment, the DR antagonist induces 
<!-- EPO <DP n="21"/>-->
 differentiation or cell death of a cancer stem cell. In one embodiment, the DR antagonist induces cell death of a cancer cell. Optionally, the cancer cell may be in vivo or in vitro. The cancer cell may be a precancerous cell such as a myelodyplastic or myeloproliferative cell. In one embodiment, the cancer cell is a hematological cancer cell. In one embodiment, the cancer cell is a leukemic cell, such as a cell from a subject with AML. In one embodiment, the DR receptor antagonist is a phenothiazine derivative such as thioridazine or chlorpromazine. In one embodiment, the DR antagonist is selected from the compounds listed in Table 1 . </p><p id="p0132" num="0132">[0060] As shown in Example 4 and Figure 5, the Applicants have surprisingly shown that some AML cell lines and primary AML cells exhibit a relative increase in the expression of dopamine receptors compared to normal hematopoietic stem cells. Screening subjects with cancer for the expression of dopamine receptors in cancer cells may therefore serve to identify subjects who would benefit from treatment with dopamine receptor antagonists. Accordingly, in one aspect of the disclosure there is provided a method for identifying a subject with cancer suitable for treatment with dopamine receptor antagonists. In one embodiment, the method comprises determining the expression of one or more dopamine receptors in a sample of cancer cells from a subject. Subjects with cancer cells that express one or more dopamine receptors are thereby identified as suitable for treatment with dopamine receptor antagonists. For example, the expression of one or more dopamine receptors in a sample of cancer cells can be determined by testing the cancer cells for polypeptides or polynucleotides that encode for dopamine receptors as described herein. In one embodiment, the method includes obtaining or providing a sample of cancer cells from the subject and/or testing the sample for the expression of one or more dopamine receptors. In one embodiment, the cancer is leukemia and the cancer cells are leukemic cells. In one embodiment, the cancer is AML. Optionally, the method includes determining additional markers known to be associated with cancer, hematological malignancies, leukemia or AML or markers associated with specific treatment 
<!-- EPO <DP n="22"/>-->
 regimes. In one embodiment, cancer cells are also tested for the monocytic marker CD 14. </p><p id="p0133" num="0133"> [0061] The expression of dopamine receptors has been observed in samples of breast cancer and AML and can serve as a biomarker for the severity of disease. As shown in Example 1 1 and Figures 14g-h, high levels of DR expression correlate with poor prognosis while low levels demonstrate a better prognosis. Accordingly, in one aspect of the disclosure there is provided a method of determining a prognosis for a subject with cancer. In one embodiment, the method comprises determining the expression of one or more biomarkers selected from dopamine receptor (DR) 1 , DR2, DR3, DR4, DR5 and CD 4 in a sample of cancer ceils from the subject and comparing the level of expression of the one or more biomarkers to a control. In one embodiment, an increase in the level of expression of the one or more biomarkers relative to the control indicates that the subject has a more severe form of cancer. Optionally, the methods described herein include providing or obtaining a sample of cancer cells from the subject such as a blood sample containing leukemic cells or a tumour sample. In one embodiment, the cancer cells are leukemic cells or breast cancer cells and increased expression of one or more biomarkers compared to the control indicates a more severe form of leukemia or breast cancer. Optionally, additional biomarkers known to be associated with cancer or severity of disease are also tested and compared to control samples. A skilled person will appreciate selecting a control that is representative of a particular prognosis in subjects with cancer such that observing a difference or similarity in the level of the one or more of the biomarkers described herein between the test sample with the control provides a corresponding prognosis for the test subject. For example, in one embodiment the control represents subjects diagnosed with AML known to have a particular outcome or prognosis and observing an increase in the level of expression of one or more dopamine receptors relative to the control indicates a worse prognosis for the subject relative to the control. 
<!-- EPO <DP n="23"/>-->
 [0062] The methods described herein are also useful for identifying subjects with cancer. In one embodiment, the methods described herein are useful for identifying subjects with leukemia, such as AML or monocytic leukemia. Accordingly, in one embodiment, there is provided a method for identifying a subject with leukemia comprising providing a sample from a subject and testing the sample for the expression of one or more biomarkers selected from DR1 , DR2, DR3, DR4 and DR5. In one embodiment, the sample comprises cancer cells such as leukemic cells and/or white blood cells. In one embodiment, the method comprises comparing the level of expression of one or more biomarkers to a control. In one embodiment, increased expression of DRs in the sample compared to the control is indicative of cancer. In one embodiment, an increased expression of DRs in the subject compared to the control is indicative of leukemia. In one embodiment, increased expression of DRs in the subject compared to the control is indicative AML or monocytic leukemia. Optionally, the methods described herein may be used in combination with other diagnostic methods for the identification of cancers or leukemia as known to a person of skill in the art. </p><p id="p0134" num="0134"> [0063] As shown in Example 1 1 , dopamine receptor expression demarcates human cancer stem cells from other cells such as normal hPSCs that express the pluripotent marker SSEA3. Accordingly, in one embodiment, there is provided a method of identifying a cancer stem cell from a population of cells comprising determining whether a cell expresses one or more biomarkers selected from dopamine receptor (DR) 1 , DR2, DR3, DR4 and DR5. In one embodiment, expression of DR1 , DR2, DR3, DR4 or DR5 is indicative that the cell is a cancer stem cell. Optionally, expression of 2 or more, 3 or more, 4 or more or all 5 DRs is indicative that the cell is a cancer stem cell. In one embodiment, a cell that expresses DR1 , DR2, DR3, DR4 and DR5 is identified as a cancer stem cell. </p><p id="p0135" num="0135">[0064] In one embodiment, the cancer stem cell is identified from a population of cells. In one embodiment the population of cells contains more 
<!-- EPO <DP n="24"/>-->
 than one cell type, such as somatic cells, pluripotent stem cells, cancer cells and/or cancer stem cells. In one embodiment, the population of cells is a plurality of cells in cell culture, such as tissue culture. In one embodiment, the population of cells is from a mammal, such as a primary tissue sample or blood sample. In one embodiment, the population of cells is from a mammal with cancer or suspected of having cancer. In one embodiment, the population of cells includes stem cells, somatic stem cells and/or pluripotent stem cells as well as one or more cancer stem cells. In one embodiment, the population of cells includes cancer cells or pre-cancerous cells such as hematological cancer cells. In one embodiment, the population of cells includes monocytic cells. In one embodiment, the population of cells includes breast cancer cells. Optionally, the population of cells is from a tissue sample, such as a tumor sample, that has been dissociated into single cells. </p><p id="p0136" num="0136"> [0065] In one aspect of the method, the step of determining whether the cell expresses one or biomarkers comprises testing the cell for the expression of polynucleotides or polypeptides that code for DR1 , DR2, DR3, DR4 or DR5. For example, methods known in the art such a RT-PCR or reporter genes that detect the expression of polynucleotides, or immunohistochemical methods that detect expression of polypeptides, can be used for determining the expression of a biomarker such as DR1 , DR2, DR3, DR4 or DR5. In one embodiment, the biomarkers are cell surface biomarkers and the method involves detecting DR1 , DR2, DR3, DR4 or DR5 expressed on the surface of the cell. </p><p id="p0137" num="0137"> [0066] In one embodiment, the methods for identifying a cancer stem cell described herein include determining the level of expression of one or more biomarkers selected from dopamine receptor (DR) 1 , DR2, DR3, DR4 and DR5 and then comparing the level of expression to a control level. For example, in one embodiment the control represents cells that are not cancer stem cells, such as somatic stem cells, hematopoietic stem cells or cells that express the pluripotency marker SSEA3, and cells that have an increased level of expression of the biomarkers DR1 , DR2, DR3, DR4 and/or DR5 
<!-- EPO <DP n="25"/>-->
 compared to the control are identified as cancer stem cells. Optionally, cells that have an increased amount of expression compared to the control are identified as cancer stem cells (e.g. at least 2X, 5X, or 10X etc.). </p><p id="p0138" num="0138"> [0067] In one embodiment, the method can also comprise: (a) providing a population of cells (b) contacting the population with an agent that specifically binds to one or more biomarkers selected from DR1 , DR2, DR3, DR4 and DR5; and (c) selecting cells that specifically bind to the agent of (b) thereby identifying and/or isolated cancer stem cells from a population of cells. In one embodiment, the agent is an antibody that selectively binds to a biomarker. In one embodiment, the methods described herein can optionally include two or more selection or isolation steps. The methods described herein can also include a negative step selection, e.g., excluding cells that express one or more markers expressed in cells that are not cancer stem cells, or excluding cells that show reduced levels of expression of a particular marker. </p><p id="p0139" num="0139"> [0068] In one embodiment, the present disclosure includes isolating cancer stem cells from a population of cells. For example, in one embodiment, cells that are identified as cancer stem cells are isolated from cells that are not cancer stem cells or from other materials in a sample by selecting for or isolating cells that express one or more biomarkers selected from DR1 , DR2, DR3, DR4 and DR5. Optionally, the cancer stem cells are isolated or selected using methods known in the art for sorting cells based on the expression of one or more biomarkers. For example, in one embodiment the step of isolating the cancer stem cells form the population of cells comprises flow cytometry, fluorescence activated cell sorting, panning, affinity column separation, or magnetic selection. In one embodiment, cells that express one or more dopamine receptors are isolated using a binding agent that selectively bind to dopamine receptors that is conjugated to a support such the matric in a separation column or magnetic beads. </p><p id="p0140" num="0140">[0069] In one aspect of the disclosure, the methods described herein include determining the level of one or more biomarkers in a sample from a 
<!-- EPO <DP n="26"/>-->
 subject, such as the level of one or more dopamine receptors. In one embodiment, the sample comprises cancer cells or is suspected of comprising cancer cells or pre-cancerous cells. For example, the sample can comprise a blood sample, for example a peripheral blood sample, a fractionated blood sample, a bone marrow sample, a biopsy, a frozen tissue sample, a fresh tissue specimen, a cell sample, and/or a paraffin embedded section. In one embodiment, the subject has or is suspected of having AML and the sample comprises mononuclear cells. In certain embodiments, the sample is processed prior to detecting the biomarker level. For example, a sample may be fractionated (e.g. by centrifugation or using a column for size exclusion or by FACS using a biomarker for monocytes), concentrated or processed, depending on the method of determining the level of biomarker employed. </p><p id="p0141" num="0141"> [0070] The level of expression of the biomarkers described herein can be determined by methods commonly known to one of skill in the art. For example, in one embodiment, the level of one or more biomarkers is determined by measuring or detecting the level of a nucleic acid such as mRNA, or the level of a protein or polypeptide. In one embodiment, expression of the one or more biomarkers is determined by detecting the cell surface expression of DR1 , DR2, DR3, DR4 and/or DR5. In one embodiment, the methods described herein include detecting a biomarker using immunohistochemistry, such as by using an antibodies specific for the biomarker or another biomarker-specific detection agent. Examples of dopamine receptor antibodies suitable for use in the methods described herein are also listed in Example 7 of the present disclosure. </p><p id="p0142" num="0142">[0071] In one embodiment, the level of an mRNA encoding for a biomarker is determined by quantitative PCR such as RT-PCR, serial analysis of gene expression (SAGE), use of a microarray, digital molecular barcoding technology or Northern blot. A person skilled in the art will appreciate that a number of methods can be used to determine the level of a biomarker, including mass spectrometry approaches, such as multiple reaction monitoring (MRM) and product-ion monitoring (PIM), and also including 
<!-- EPO <DP n="27"/>-->
 antibody based methods such as immunoassays such as Western blots and enzyme-linked immunosorbant assay (ELISA). In certain embodiments, the step of determining the expression of a biomarker such as one or more dopamine receptors as described herein, comprises using immunohistochemistry and/or an immunoassay. In certain embodiments, the immunoassay is an ELISA. In yet a further embodiment, the ELISA is a sandwich type ELISA. </p><p id="p0143" num="0143"> [0072] The term "level" as used herein refers to an amount (e.g. relative amount or concentration) of biomarker that is detectable or measurable in a sample. For example, the level can be a concentration such as pg/L or a relative amount such as 1 .2, 1.3, 1.4, 1.5, 1.6, 1 .7, 1 .8, 1.9, 2.0, 2.2, 2.4, 2.6, 2.8, 3.0, 3.2, 3.4, 3.6, 3.8, 4.0, 4.2, 4.4, 4.6, 4.8, 5.0, 10, 15, 20, 25, 30, 40, 60, 80 and/or 100 times or greater a control level, standard or reference level. Optionally, a control is a level such as the average or median level in a control sample. The level of biomarker can be, for example, the level of protein, or of an mRNA encoding for the biomarker such as a dopamine receptor. </p><p id="p0144" num="0144"> [0073] In one embodiment, when the level of two or more biomarkers is determined, the levels of the two or more biomarkers can be used to generate an expression profile for the subject. For example, in one embodiment, the methods described herein include determining a level for two or more biomarkers in the sample, generating an expression profile based on the level of the two or more biomarkers and comparing the expression profile to a control expression profile. A difference or similarity in the test sample expression profile and the control expression profile is then used to provide a prognosis for the test subject, identify the subject as having cancer, or indicate whether the subject is suitable for treatment with a dopamine receptor antagonist. </p><p id="p0145" num="0145"> [0074] A further aspect of the disclosure includes the use of a dopamine receptor antagonist for the treatment of cancer or a precancerous disorder. In a similar aspect, there is provided a dopamine receptor antagonist for use in the treatment of cancer or a precancerous disorder. In one 
<!-- EPO <DP n="28"/>-->
 embodiment the cancer is leukemia. In one embodiment, the leukemia is acute myeloid leukemia or monocytic leukemia. In one embodiment, the dopamine receptor antagonist is a phenothiazine derivative such thioridazine or chlorpromazine. In one embodiment, the DR antagonist is selected from the compounds listed in Table 1 . </p><p id="p0146" num="0146"> [0075] Also disclosed herein is the use of a dopamine receptor antagonist for the manufacture of a medicament for the treatment of a cancer and/or a precancerous disorder. </p><p id="p0147" num="0147"> [0076] A further aspect of the disclosure includes methods of screening compounds for anti-cancer activity comprising identifying compounds that antagonize one or more dopamine receptors. In one embodiment, compounds that antagonize dopamine receptors are identified as having anticancer activity. In one embodiment, the methods include screening compounds to identify those that reduce the proliferation of cancer stem cells relative to normal stem cells such as hematopoietic stem cells as set out in Examples 7 and 8 of the present description. </p><p id="p0148" num="0148"> [0077] The following non-limiting examples are illustrative of the present disclosure: </p><p id="p0149" num="0149"> Examples </p><p id="p0150" num="0150">Example 1 : Thioridazine is cytotoxic to leukemic cell lines </p><p id="p0151" num="0151"> [0078] The effect of Thioridazine on normalized cell number was evaluated in 3 leukemic cells lines: HL-60, MV4-1 and OCI-AML3. All three lines are leukemic cell lines. HL-60 was derived from promyelocytic AML whereas MV 4-1 1 and OCI-AML3 are representative of AML. Each compound was incubated with the cells for 72h. The control was DMSO (ie the vehicle used for the compound) for 72h. Each condition had three replicates. </p><p id="p0152" num="0152"> [0079] As shown in Figure 1 , doses of 0.1 μΜ and 1 μΜ thioridazine had little effect on normalized cell number, while at 10 μΜ the normalized cell number was reduced to almost zero. 
<!-- EPO <DP n="29"/>-->
 Example 2: Differential activity of thioridazine on AML blast-forming potential and colony forming potential of normal stem cells </p><p id="p0153" num="0153"> [0080] The effects of thioridazine on blast formation in an AML cell line was compared to the effect of thioridazine on colony formation in normal human stem cells. </p><p id="p0154" num="0154"> [0081] Normal HSCs and progenitors were sourced from either mobilized peripheral blood or umbilical cord blood of health patients. Primary AML cells were taken from patients diagnosed with AML. Both normal HSCs and primary AML cells were cultured under standard in vitro methocellulose assay conditions (see http://www.stemcell.com/en/Products/AII- Products/MethoCult-H4434-Classic.aspx as well as Clinton Campbell et al. The human stem cell hierarchy is defined by a functional dependence on Mcl- 1 for self-renewal capacity. Blood 116 (9) 1433-1442 (June 4, 2010), hereby incorporated by reference) for at least 14 days before the number of colonies were recorded. As shown in Figure 2, 10 μΜ thioridazine has a differential effect on normal HSCs versus AML cells. 10 μΜ thioridazine reduced the colony forming potential of normal HSCs from about 100 (CTRL treated with DMSO) to about 66 total colonies (Fig 2A), but had a much more significant effect on AML cells reducing the number of CFU colonies to about 22 blast colonies (Fig 2B) to 1.6 blast colonies. </p><p id="p0155" num="0155"> [0082] Figure 3 shows cell pellets of CFU colonies generated from normal HSC and AML treated with thioridazine. At a dose of 10 μΜ, pelleted cells are still visible for HSCs, but not for AML cells. Thioridazine therefore selectively targets Blast-CFU Potential of AML cells. </p><p id="p0156" num="0156">Example 3: Chlorpromazine is toxic to AML cell lines </p><p id="p0157" num="0157"> [0083] The dopamine receptor antagonist and phenothiazine-related compound chlorpromazine was also investigated for effects on the AML cell lines HL-60, MV4-1 1 and OCI-AML3. Testing was performed as set out in Example 1. As shown in Figure 4, 10 μΜ Chlorpromazine is toxic to AML cell lines. 
<!-- EPO <DP n="30"/>-->
 Example 4: Expression of dopamine receptors in normal blood versus leukemia </p><p id="p0158" num="0158"> [0084] The expression of the dopamine receptors DR1 , DR2, DR3, DR4 and DR5 were analyzed in AML cell lines HL-60, MV4-11 , AML-OCI2 and AML-OCI3), Primary AML cells (AML22101 , AML29428, AML22174, AML29560) isolated from AML patients, normal blood mononuclear cells (MNC) (MPB21471 and MPB28137; healthy patient blood) as well as umbilical cord blood primary cells enriched for normal Human Stem Cells or progenitors (CB107, CB108 and CB109) using StemSep® Human Hematopoieitc Progenitor Cell enrichment kit</p><p id="p0159" num="0159">(http://www.stemcell.com/en/Products/AII-Products/StemSep-Human- Hematopoietic-Progenitor-Cell-Enrichment-Kit.aspx) and enrichment levels of HSCs/Human Progenitor cells confirmed by flow cytometry. Isotype expression was measured as background. Peaks to the right of the isotype peak represent positive expression of DR markers. </p><p id="p0160" num="0160"> [0085] As shown in Figure 5, dopamine receptors are expressed on primary AML, AML cell lines and normal mononuclear blood cells (MNC) but not in blood enriched for normal HSCs (CB(lin-). The data shows that when the sample is positive for DR expression that all five DR subtypes are usually present. </p><p id="p0161" num="0161"> [0086] Not all primary AMLs were observed to express dopamine receptors. Accordingly, subjects may be pre-screened for the expression of dopamine receptors in order to identify subjects suitable for AML treatment with DR antagonists. Optionally, pre-screening of subjects may encompass all five DR subtypes, or specific subtypes or combination of subtypes. </p><p id="p0162" num="0162"> Example 5: Multiple DR antagonists are cytotoxic to AML cell lines </p><p id="p0163" num="0163"> [0087] A series of dopamine receptor agonists, D<sub>3</sub>. antagonists, DRi &amp; <sub>5</sub>- antagonists and multi-receptor antagonists were tested for cytotoxicity against three AML cell lines HL-60, OCI-AML2 and OCI-AML3. Testing was performed as set out in Example 1. 
<!-- EPO <DP n="31"/>-->
 [0088] As shown in Figure 6, CLOZ at higher concentrations as well as CHL and THIO have a significant effect on cytotoxicity of AML cell lines. Without being limited by theory, the cytotoxic effect may require inhibition of multiple dopamine receptors. THIO, CHL and CLOZ being multireceptor antagonists work to eradicate the AML cell lines while the D<sub>3</sub> and DRi &amp; <sub>5</sub>- specific antagonists only reduce cell count to 60%. </p><p id="p0164" num="0164"> Example 6: Dopamine receptors are expressed in the CD14+ cell population of primary AML </p><p id="p0165" num="0165"> [0089] The expression of dopamine receptor subtypes was analyzed in primary AML cells. Primary AML cells obtained from AML patients were co- stained with antibodies specific to the DR subtype and CD14 prior to being analyzed using flow cytometry. The majority of DR+ cells were found to be positive for CD14. </p><p id="p0166" num="0166"> [0090] As shown in Figure 7, the expression of the CD14 monocytic marker is correlated with the expression of each DR subtype. </p><p id="p0167" num="0167"> [0091] The effects of thioridazine were also examined on a subpopulation of CD14+ cells in primary AML. Primary AML cells were cultured under control (DMSO vehicle) or 10uM thioridazine for 72h and then stained for with antibodies specific to CD14. The number of CD14+ cells in both control and thioridazine treated samples was determined using flow cytometry and the frequency of CD 14+ cells was found to be lower in the thioridazine treated sample, suggesting that this compound selectively targets the CD14+ subpopulation in AML cells. </p><p id="p0168" num="0168"> [0092] As shown in Figure 8, 10 μΜ thioridazine also reduced the normalized frequency of CD14+ cells in primary AML cells, showing that thioridazine selectively targets CD14+ cells. The AML control group contained a fraction of CD14+ cells. This fraction is reduced with thioridazine treatment and is represented as a reduction in the normalized frequency of the control (100%) versus treated (20%). 
<!-- EPO <DP n="32"/>-->
 Example 7: Identification and characterization of drugs that induce differentiation of hPSCs </p><p id="p0169" num="0169"> Identification of drugs that target cancer stem cells (CSCs) without affecting normal stem cells (SCs) would be ideal for future cancer therapies, but is limited by the lack of assays for both CSCs and normal SCs in the human that are amenable to robust biological screens. As set out in the following examples, using a neoplastic vs. normal human pluripotent stem cell (hPSC) differentiation platform, compounds were identified that are not toxic, but induce differentiation to overcome neoplastic self-renewal of CSCs. Of the several candidate anti-CSC agents identified, thioridazine, an approved antipsychotic drug, was able to selectively target human somatic CSCs capable of in vivo leukemic disease initiation while having no effect on normal blood SC capacity. Antagonism of dopamine receptor (DR) signaling by thioridazine forms the basis of selective CSC targeting, and revealed DR as a biomarker for CSCs of hematopoietic and breast tumor origins. </p><p id="p0170" num="0170"> Experimental Procedures </p><p id="p0171" num="0171"> [0093] Generation of neoplastic hPSC EOS-GFP lines. Neoplastic v1 H9 or v2H9 hPSC cells (Werbowetski-Ogilvie et al., 2009) were transduced with lentivirus bearing the EOS-C3+ or EOS-S4+ vectors provided by Dr James Ellis (Hotta et al., 2009). After lentiviral transduction cells were selected using Puromycin, and subsequently sorted as single cells into a 96- well plate based on GFP expression using a FASCAria II (Becton-Dickinson). Colonies generated from single cell clones were used to establish the v1 H9- Oct4-GFP (EOS-C3+), v2H9-Oct4-GFP (EOS-C3+) and v H9-Sox2-GFP (EOS-S4+) lines. </p><p id="p0172" num="0172"> [0094] Cell culture. The H9 hESC, v1 H9, v1 H9-Oct4-GFP, v2H9-Oct4- GFP, v1 H9-Sox2-GFP and fibroblast-derived iPSCs were cultured as previously described (Chadwick et al., 2003; Werbowetski-Ogilvie et al., 2009). 
<!-- EPO <DP n="33"/>-->
 [0095] Primary human samples. For AML specimens, peripheral blood and/or bone marrow was collected at the time of clinical presentation. Healthy hematopoietic cells were obtained from umbilical cord blood samples. All samples were obtained following informed consent according to Research Ethics Board approved protocols at McMaster University and the London Health Sciences Centre. Human breast tumor samples were obtained from reduction mammoplasty surgeries following informed consent according to Research Ethics Board approved protocols at McMaster University. </p><p id="p0173" num="0173"> [0096] In vitro culture platform for normal and neoplastic hPSCs. Chemical screens involved v1 H9-Oct4-GFP cells seeded at 5,000 cells per well in mouse embryonic fibroblast conditioned media (MEFCM) supplemented with 8ng/ml bFGF. 24 hours later the media was exchanged for MEFCM with compounds at 10μΜ and 0.1 % DMSO, 0.1 % DMSO (-BMP4) or 100ng/ml of BMP4 and 0.1 % DMSO (+BMP4) for 48 hours before being exchanged with fresh media with compound for a further 24h (total compound treatment time 72h) prior to being fixed and prepared for automated imaging and plate reader analysis. Confluent H9 &amp; fibroblast-derived iPSC were seeded at 10,000 ceils per well in MEFCM supplemented with 8ng/ml bFGF. 24 hours later the cells were treated with compounds at 10μΜ and 0.1 % DMSO, 0.1 % DMSO (-BMP4) or 100ng/ml of BMP4 and 0.1 % DMSO (+BMP4). Fresh MEFCM supplemented with compounds was exchanged daily for 5 days. On day 5, hPSC's were fixed and prepared for automated imaging and plate reader analysis. See supplementary experimental procedures for further details. </p><p id="p0174" num="0174">[0097] Teratoma Assay. 400,000 H9 hESCs or v1 H9-Oct4-GFP were injected intra-testicularly into male NOD/SCID mice and teratomas analyzed for Oct4 as previously described. (Werbowetski-Ogilvie et al., 2009). </p><p id="p0175" num="0175"> [0098] Xenotransplantation assays. HOO.Cg-Prkdc<sup>sci</sup> H2rtf<sup>m1Wi</sup>'lSzJ adult mice (NSG) were sub-lethally irradiated with 315 rads 24 hours prior transplantation. 0.8-1.0 x 10<sup>7</sup> AML MNCs or 1.5-1.8 x 10<sup>5</sup> CB lin- hematopoietic cells treated with compound or DMSO-vehicle for 24h were 
<!-- EPO <DP n="34"/>-->
 W </p><p id="p0176" num="0176">33 injected via tail vein (IV). After 6-10 weeks, animals were culled, and the BM and spleen were analyzed for the presence of human cells by flow cytometry (LSRII, BD) and data was analyzed using FlowJo software (Tree Star Inc). For secondary HSPC transplants, equal number of engrafted human cells from 5 CB lin- transplants were injected IV in adult irradiated NSG mice as described for primary transplants. </p><p id="p0177" num="0177"> [0099] Statistical analysis. Data is represented as the mean ± SEM or mean ± SD. Significant differences between groups were determined using unpaired two-way or one-way Students' t test. </p><p id="p0178" num="0178"> 10 [00100] Pluripotent stem cell culture. The H9 hESC, v1 H9, v1 H9- Oct4-GFP, v2H9-Oct4-GFP, v1 H9-Sox2-GFP and fibroblast-derived iPSCs were cultured on Matrigel™-coated (BD Biosciences 353234) plates with mouse embryonic fibroblast-conditioned (MEFCM) media supplemented with 8 ng/ml bFGF (GIBCO 13256-029). MEFCM is composed of KO-DMEM</p><p id="p0179" num="0179">15 (GIBCO 10829-018), 20% KO-Serum Replacement (GIBCO 10828-028), 1 % Non-Essential Amino Acids (GIBCO 1 1 140-050), 1 mM L-Glutamine, 0.1 mM β- mercaptoethanol (Sigma Aldrich M7522). Cell lines were passaged every 7 days using 100 Units/mL of Collagenase IV (GIBCO 17104-019) for 2-3 minutes. Cell seeding density, assay duration and DMSO vehicle</p><p id="p0180" num="0180">20 concentration in 96 wells were optimized for v1 H9-Oct4-GFP cells and normal H9 hPSC. For v H9-Oct4-GFP, an optimum initial seeding density of 5,000 cells per well for 72h of treatment was selected based on maximal levels of GFP and z' discrimination between ±BMP4 controls. For normal hPSC, an optimal seeding density of 10,000 cells per well was selected based on</p><p id="p0181" num="0181">25 maximal z'-prime discrimination between ±BMP4 controls. </p><p id="p0182" num="0182"> [00101] Primary human samples. Mononuclear cells were prepared using Ficoll-Paque Premium (GE Healthcare). For hematopoietic cells, lineage depletion was performed using EasySep (StemCell Technologies) following manufacturer's recommendations. </p><p id="p0183" num="0183"> 30 [00102] AML/HPSC cell culture. AML cell lines, namely, OCI-AML2 (M4), OCI-AML3 (M4), HL-60 (M2) and MV-4-11 (M5) were cultured in RPMI 
<!-- EPO <DP n="35"/>-->
 (Gibco) supplemented with 5% heated-inactivated FBS (HyClone). For DR agonist studies with R(+)-7-Hydroxy-DPAT hydrobromide (Sigma), serum-free conditions were employed instead due to the prevalence of dopamine in FBS (Little et al., 2002). AML patient blasts were cultured in IMDM supplemented with 5% heated inactivated FBS (HyClone), 5 ng/mL IL3 (R&amp;D systems), 5 x 10<sup>"5</sup> M β-mercaptoethanol (Sigma) and BIT (StemCell Technologies). HSC media contained IMDM supplemented with 1 % BSA (Sigma), 100 ng/mL SCF (R&amp;D systems), 100 ng/mL Flt-3L (R&amp;D systems) and 20 ng/mL TPO (R&amp;D systems). Patient HSPC and AML samples were treated with compound or DMSO-vehicle (0.1 %) for 24h prior to CFU plating or xenotransplantation studies. </p><p id="p0184" num="0184"> [00103] Antibodies. Antibodies used for immunocytochemistry were the following: Oct3/4 (BD Trunsduction Laboratories, cat#61 1203), Sox2 (R&amp;D, cat#AF2018). To detect human hematopoietic cells, Pacific Blue-, PE-, APC- or FITC labeled anti-human CD45 was used (BD Biosciences). FITC anti- CD33, PE anti-CD13, FITC anti-CD41a, FITC anti-HLA DR, and PE anti- CD19 antibodies were obtained from BD Pharmingen. PE anti-CD14, PE anti- CD15 and PE anti-GlyA were acquired from Immunotech Beckman Coulter. To determine pluripotency, PE anti-SSEA3 (BD Biosciences) and PE- or AlexaFluor488 anti-Oct4 (BD Biosciences). Rabbit anti-human dopamine receptor antibodies; DRD1 (Cat#324390), DRD2 (Cat#324393), DRD3 (Cat#324402), DRD4 (Cat#324405) and DRD5 (Cat#324408) were sourced from EMD Chemical. Anti-rabbit Alexa-Fluor-488 (Molecular Probes) was used as the secondary antibody. Primary anti-p53 (Cat#2527) and anti-p21 (Cat#2947) rabbit IgG sourced from Cell Signaling Technology were used to stain fixed and permeabilized cells. Anti-rabbit alexa-Fluor-546 (Molecular Probes) was used as the secondary antibody. For breast tumor staining, APC anti-CD44 and PE-CD24 were sourced from BD Pharmingen. </p><p id="p0185" num="0185"> Automated Imaging and Analysis </p><p id="p0186" num="0186">[00104] Imaging neoplastic hPSC. Cells were fixed in 2% paraformaldehyde and stained with l Opg/mL Hoechst 33342 (Invitrogen) with 
<!-- EPO <DP n="36"/>-->
 a Combi Multidrop Dispenser (Thermo). For experiments that involved Oct4 immunocytochemistry, a monoclonal antibody for Oct4 (BD) was used along with an Alexa-Fluor-647 secondary (Invitrogen). Immunocytochemical staining was performed by a Janus automated liquid handler (Perkin Elmer). Images were acquired at 10x N.A with an Arrayscan HCS VTI Reader (Cellomics) by means of epi-fluorescence illumination and standard filter sets. </p><p id="p0187" num="0187"> [00105] Imaging normal hPSC. Cells were fixed in 2% paraformaldehyde and stained with 1 Q^g/ml_ Hoechst 33342 (Invitrogen). Standard fluorescence immunocytochemical techniques were used to stain the cells with a monoclonal antibody for Oct4 (BD), and an Alexa-Fluor-647 secondary antibody (Invitrogen). All steps were performed by a Janus automated liquid handler (Perkin Elmer). Images were acquired at 5x with an Arrayscan HCS Reader (Cellomics) by means of epi-fluorescence illumination and standard filter sets. </p><p id="p0188" num="0188">[00106] Image Analysis. Image analysis was performed using custom scripts in Acapella software (Perkin Elmer). Nuclear objects were segmented from the Hoechst signal. For neoplastic cell lines, object intensity analysis was performed on GFP positive cells only. For normal cell lines, the fraction of Alexa-Fluor-647-positive cells was quantified. Images and well-level data were stored and analysed in a Columbus Database (Perkin Elmer) and further data analysis, compounds registration and hit identification in ActivityBase (IDBS). </p><p id="p0189" num="0189"> [00107] Gene expression analysis. Cells in specific conditions were collected and RNA was extracted by using RNeasy kit (Qiagen), complementary DNA (cDNA) generation by using Superscript III® cDNA synthesis kit (Invitrogen), pre-amplification and TaqMan® array reaction (Applied Biosystems) were performed according to manufacturer's instructions. The gene expression profile for each treated cell population was analyzed using TaqMan® Stem Cell Pluripotency Array Card on ViiA 7 Real- Time PCR System (Applied Biosystems). Each reaction sample was dispensed into loading wells on the array card and centrifuged twice at 336 X 
<!-- EPO <DP n="37"/>-->
 g for 1 min each time, sealed, and placed in the thermal cycler. The following cycling conditions were used for all array card applications: 45°C for 10 min, 94°C for 10 min, and 40 cycles of 94°C for 30s followed by 60°C for 1 min. Array data were normalized to 18S RNA and GAPDH and comparisons were performed using data analysis 2.0 software (Applied Biosystems). </p><p id="p0190" num="0190"> [00108] Methylcellulose colony-forming assay. AML patient or CB lin- cells were cultured 24 hours in the presence of compound or DMSO- vehicle (0.1 %) control. AML cells were plated at 50 000 cells/mL in Methocult GF H4434 (Stem Cell Technologies). CB lin- cells were plated at 1000 cells/mL in Methocult GF H4434 (Stem Cell Technologies). Colonies were scored after 14 days of culture using standard morphological criteria. </p><p id="p0191" num="0191"> [00109] Volumetric cell counting. The number of AML-OCI2 and AML-OCI3 cells present after 72h treatment with DR antagonists (Fig 16b) and agonist (Fig 6c-d) were counted by measuring the number of events within a fixed volume following the grating strategy defined by forward scatter and side scatter clustering, 7AAD- and Hoechst+. </p><p id="p0192" num="0192"> [00110] Human breast cancer sample processing. Human breast tumor samples were obtained from reduction mammoplasty surgeries following informed consent according to Research Ethics Board approved protocols at McMaster University. The breast tumor chunks were cut into small fragments (chunks of less than 1 mm) with scissors and scalpel. Subsequently, 3mL of Versene (1 mL of 0.5M EDTA in 1 L of 1X PBS) and 7ml_ of trypsin-collagenase solution were added for each gram of tumor tissue and incubated for 30min at 37<sup>°</sup>C. The trypsin-collagenase solution consisted of RPMI 1640 (Gibco #11875093), 2% penicillin/streptomycin (Invitrogen #15140163), 1 % Fungizone Antimycotic (Invitrogen #15290018), 2% FBS, 3mg/ml_ Collagenase A (Roche Diagnostics #11088793001 ), and 0.1 % of 2.5% trypsin (Gibco #15090). An equal volume of RPMI 1640 with 2% FBS was then added to the 
<!-- EPO <DP n="38"/>-->
 tissue suspension. The tissue suspension was filtered through a 40μηη nylon strainer (Falcon #352340). The supernatant was discarded and the cell pellet was resuspended in 10mL of F-12+GlutaMAX Nutrient Mixture Ham 1X (Gibco #31765) supplemented with 2% penicillin/streptomycin and 1 % Fungizone Antimycotic. Viable cells were counted using a hemocytometer and Trypan blue solution and prepared for flow cytometry. Antibody staining included Rabbit anti-human dopamine receptor antibodies; DRD1 (Cat#324390), DRD2 (Cat#324393), DRD3 (Cat#324402), DRD4 (Cat#324405) and DRD5 (Cat#324408) were sourced from EMD Chemical and Anti-rabbit Alexa-Fluor-488 (Molecular Probes) was used as the secondary antibody along with APC anti- CD44 and PE-CD24, both sourced from BD Pharmingen. </p><p id="p0193" num="0193"> Example 8: High throughput screening identification of compounds that induce differentiation of neoplastic hPSCs </p><p id="p0194" num="0194">[00111] The inventors have previously described a variant human pluripotent stem cell (hPSC) line that displays neoplastic features which include enhanced self-renewal and survival, along with aberrant block in terminal differentiation capacity in vitro and in vivo (Werbowetski-Ogilvie et al., 2009). Based on these similarities in functional properties to somatic CSCs, neoplastic hPSCs were examined as a surrogate for somatic CSCs that would be amenable for high content and high throughput screening in vitro. A screening platform was developed to identify small molecules that selectively target neoplastic hPSCs whilst having little effect on normal hPSCs. This differential screening platform is capable of identifying potent candidate drugs that selectively target somatic CSCs while sparing healthy SC capacity. </p><p id="p0195" num="0195"> [00112] Oct4 and Sox2 provide a reliable indicator of loss of self- renewing pluripotent state and differentiation induction of normal and neoplastic hPSCs. To provide a more straightforward method for detecting loss of Oct4 or Sox2 during induced differentiation of neoplastic hPSCs, GFP- reporter lines were generated by transduction of neoplastic hPSCs with the EOS-GFP reporter (v1 H9-Oct4-GFP and v1 H9-Sox2-GFP, respectively) 
<!-- EPO <DP n="39"/>-->
 (Hotta et al., 2009). GFP intensity was observed to be correlated with Oct4 and Sox2 expression in treatments that favored self-renewal stability and conditions that induce differentiation with the addition of BMP4. This response was consistently found using an additional neoplastic hPSC line, v2H9 (Werbowetski-Ogilvie et al., 2009) transduced with the same EOSIentivirus GFP-reporter (v2H9-Oct4-GFP), as well as a Sox2 reporter line (v1 H9-Sox2- GFP). </p><p id="p0196" num="0196"> [00113] The uniform response to differentiation and maintenance of pluripotency in all hPSC cell lines generated also revealed that viral integration or clonal selection by EOS reporter construct insertion is irrelevant to responsiveness. These results suggest that compounds that induce differentiation can be identified based on the reduction of GFP intensity in neoplastic hPSC reporter lines and could be exploited for chemical screening. To that end, conditions for automated high content microscopy and fluorimetric-based high throughput screening were used to detect reductions in pluripotency marker expression of hPSCs. Microscopic analysis of normal hPSCs showed that distinct Oct4+ cells are lost following BMP4 treatment. Similarly, the reduction in both GFP and Oct4 due to BMP4 treatment of neoplastic Oct4-GFP hPSCs was quantified by high content microscopy and plate reader-based fluorimetry. To identify ideal candidates for targeting CSCs differentiation of both normal and neoplastic hPSCs in response to compound treatment was assessed in parallel. </p><p id="p0197" num="0197"> [00114] Given the validation of the screening platform a chemical libraries composed of 590 well-established annotated compounds from the NIH Clinical Collection and Canadian Compound Collection was screened. These Collections have been previously scrutinized in numerous other mammalian cell lines (Diallo et al., 2010; Shoemaker, 2006). Following the demonstration that fluorometric highthroughput screening (HTS) and high content screening (HCS) platforms give equivalent measurements for loss of pluripotency (GFP RFU and mean GFP intensity per cell, respectively) and cell count (Hoechst RFU and Cell count, respectively) of the 51 defined 
<!-- EPO <DP n="40"/>-->
 compounds, HTS was selected as the preferred platform for more rapidly screening compound libraries (Fig 9a). Of the 590 compounds screened (at 10μΜ based on previous studies (Inglese et al., 2007)), 1 1 compounds were identified to induce differentiation as indicated by a reduction in both GFP % residual activity (%RA) and Hoechst %RA (Figs 9b-c). A total of 4 of these compounds; indatraline, thioridazine, azathioprine, and mefloquine, were identified as candidate compounds based on clustering and levels of Hoechst %RA in excess of 30% (Fig 9b). Secondary high content analysis revealed indatraline to be a questionable candidate and was thus excluded, whereas content analysis and HTS analyses dually confirmed thioridazine, azathioprine, and mefloquine as candidate compounds (Fig 9d) and were thus selected for further testing (Figs 9e-g). When compared to control-treated hPSCs, each compound appeared to induce distinct morphological changes in neoplastic hPSCs (Fig 9e). Reduction in GFP intensity was confirmed using image analysis (Fig 9f) and further assessed over a wide range of doses to calculate half-maximal effective concentration (EC50) for each compound (Fig 9g). Only thioridazine and mefloquine were found to possess EC50 values lower than the 10μΜ target threshold (Fig 9g) and thus defined as candidates for further in depth evaluation using neoplastic hPSCs and somatic CSCs from patients. </p><p id="p0198" num="0198"> Example 9: Thioridazine selectively induces neoplastic hPSC differentiation and reduces human AML blasts without affecting normal hematopoietic stem/progenitor cells </p><p id="p0199" num="0199"> [00115] The responses to thioridazine and mefloquine were evaluated in both normal (Fig 10a) and neoplastic hPSCs (Fig 0b) at three concentrations using quantitative flow cytometry to detect the loss of Oct4 and reveal the degree of differentiation. Salinomycin, a reported selective inhibitor of breast CSCs (Gupta et al., 2009), was included for comparison. At 10μΜ, all compounds reduced the number of cells, but the levels of Oct4 in remaining normal hPSCs was not below levels observed with BMP4 treatment (Fig 10a). This same response was replicated in fibroblast-derived human iPS cells, (Fig 
<!-- EPO <DP n="41"/>-->
 1 1 a), representing an additional normal hPSC line from a distinct (adult) origin, indicating the effects are not specific to embryonic sources. When the same compounds were used to treat neoplastic hPSCs, mefloquine and thioridazine treatments caused reductions in cell number and the levels of Oct4 in neoplastic hPSCs. Only thioridazine was able to reduce levels of Oct4 below BMP4 differentiation controls (Fig 10b), indicating the ability of thioridazine to overcome neoplastic hPSC differentiation block. A more comprehensive dose response of all compounds was performed on neoplastic hPSCs to confirm this response (Fig 1 1 b). To identify compounds that selectively differentiate neoplastic hPSCs quantitatively, the ratio of normalized percentage of Oct4+ cells between normal and neoplastic hPSCs in response to these compounds was determined. For example, a ratio of 1 suggests equivalent differentiation whereas a ratio &gt;1 defines relatively more differentiation in neoplastic hPSCs vs. normal hPSCs. Only thioridazine, at both μΜ and 10μΜ, had a significant impact on inducing differentiation of neoplastic hPSCs over normal hPSCs (Fig 10c). Rapid accumulation of the cell stress marker p53 (Fig 10d) and its transcriptional target p21 (Fig 10e) were used to further distinguish differentiation induction from cellular toxicity. Treatment of neoplastic hPSCs with the toxic chemotherapeutic agent etoposide resulted in high levels of p53 and p21 after 24h. However, treatment with 10μΜ thioridazine or B P4, unlike agents that induce toxicity alone, resulted in no accumulation of p53 or p21 , consistent with induced differentiation rather than stress-response programs. Furthermore, thioridazine treatment led to expression of differentiation genes quantified by TaqMan Low-Density Array-qPCR in neoplastic hPSCs. An upregulation in 21 of 50 differentiation-associated genes (Fig 10f) was observed in treated neoplastic hPSCs consistent with differentiation-inducing effects of thioridazine. </p><p id="p0200" num="0200"> [00116] To examine the potential similarities in chemical response of neoplastic hPSCs to somatic CSCs, normal and neoplastic populations of the human hematopoietic system were assessed. Experimentally, self-renewal and differentiation of both human hematopoietic stem-progenitor cells 
<!-- EPO <DP n="42"/>-->
 (HSPCs) and Leukemic Stem Cells (LSCs) can be interrogated by powerful and well established in vitro and in vivo assays uniquely available to the hematopoietic system, making it an ideal tissue to evaluate the potential surrogacy of using normal and neoplastic hPSCs as a primary screening tool for anti-CSC compounds. Lineage-depleted umbilical cord blood (CB lin-) is highly enriched for HSPCs and is a reliable source of normal somatic SCs capable of self-renewal and multilineage differentiation to all blood lineages. Acute myeloid leukemia (AML) is a hematological neoplasia characterized by a block in mature myeloid differentiation that is sustained by a self-renewing LSC (Bonnet and Dick, 997; Lapidot et al., 1994). </p><p id="p0201" num="0201"> [00117] As such, progenitor assays in methylcellulose were conducted with HSPCs and 5 AML patient samples; each treated with thioridazine, mefloquine, or salinomycin in order to assess each compound's impact on in vitro clonogenic and multilineage hematopoietic differentiation. Representative cell pellets of the total colony-forming units (CFUs) generated from HSPCs (Fig 10g) and AML (Fig 0h) treated with each compound are shown. Thioridazine treatment resulted in a reduction in AML proliferation/clonogenic capacity while retaining HSPC multilineage differentiation (Fig 1 c). Changes in multilineage differentiation were quantified based on the enumeration of CFUs generated following treatment of HSPCs (Fig 10i) and AML patient (Fig 10j) samples with these compounds. At both 1 μΜ and 10μΜ salinomycin reduced AML-blast CFU potential (Fig 10j), but also reduced HSPC CFU potential over all doses tested (Fig 10i) indicative of non-specific toxicity in the hematopoietic system. In contrast, mefloquine and thioridazine reduced AML- blast CFU formation (Fig 10j) while having little effect on HSPC CFU potential (Fig 10i) and multilineage composition (Fig 1 1 d) indicating that mefloquine and thioridazine do not alter normal hematopoiesis. </p><p id="p0202" num="0202"> [00118] The most desired outcome of compounds identified toward clinical use would entail preferential elimination of AML-blast CFU generation while preserving normal HSPC progenitor capacity. The ratio between total CFUs generated from HSPC vs. AML-blasts to reveal the highest selectivity 
<!-- EPO <DP n="43"/>-->
 for targeting AML was calculated (Fig 10k). A ratio of 1 suggests equivalent normal to neoplastic progenitor potential whereas a ratio &gt;1 defines a compound that selectively reduces AML-blast CFU potential. Salinomycin (1 μΜ), mefloquine (10μΜ), and thioridazine (10μΜ) doses yielded the highest ratio values for each compound (Fig 10k) and were thus selected for in vivo evaluation. Thioridazine 10μΜ, in particular, demonstrated the highest ratio of all compounds, but most importantly was the only compound to show a significantly lower AML-blast CFU potential relative to normal HSPC CFU potential (Fig 10k). To address whether thioridazine's specificity for reducing the clonogenic potential of AML-blast CFUs was due to induction of differentiation, the frequency of CD1 1 b, a marker of granulocytic maturation, in patient AML cells was assayed in response to thioridazine treatment (Fig 101). A marked increase in the frequency of granulocytic AML-blast cells was observed with treatment duration (Fig 101) indicating that thioridazine exhibits its specific targeting of AML cells through induction of differentiation. This finding is analogous to differentiation-induction demonstrated in neoplastic hPSCs (Fig 10a-f) and confirms the robust readout of this screening platform towards identifying agents able to differentiate neoplastic cells. This result also suggests that thioridazine may represent the best candidate for specific targeting of AML CSCs that requires testing using in vivo human-mouse xenograft assays. </p><p id="p0203" num="0203"> Example 10: Thioridazine reduces LSC function while sparing normal HSPCs </p><p id="p0204" num="0204"> [00119] To delineate whether the inhibition of AML-blasts detected in vitro was due to the compounds affecting the neoplastic stem cell compartment, xenotransplantation studies (Dick, 2008) that functionally define LSCs and hematopoietic stem cells (HSCs) were conducted (Fig 12). Treatment of HSPCs with salinomycin (1 μΜ) significantly reduced hematopoietic engraftment to almost non-detectable levels (Fig 13a) revealing that this compound interferes with normal hematopoiesis from HSPCs and was thus excluded from further evaluation as it is unlikely to provide the 
<!-- EPO <DP n="44"/>-->
 selective anti-CSC therapeutic targeting desired. In contrast, mefloquine (10μΜ) treatment displayed a slight, yet insignificant, reduction in HSC capacity relative to controls (Fig 12a). However, mefloquine proved ineffective in reducing AML LSC capacity and was thus discontinued from further evaluation due to absence of selective effects (Fig 12c). </p><p id="p0205" num="0205"> [00120] In contrast to both salinomycin and mefloquine, treatment of HSPCs with thioridazine 10μΜ displayed the same level of bone marrow (BM) engraftment (Fig 12a) and splenic engraftment (Fig 13b) as control vehicle treated cells. Multilineage reconstitution capacity was identical from control- and thioridazine-treated human HSCs with myeloid (Fig 12b), lymphoid (Fig 12b), erythroid (Fig 13d), and megakaryocytic development (Fig 13d) completely unaffected. As measured by secondary serial transplantation, thioridazine treatment did not affect HSC self-renewal as compared to control- treated samples (Fig 13f). However, in sharp contrast to salinomycin and mefloquine, thioridazine treatment was able to significantly reduce leukemic disease-initiating AML LSCs (Figs 12c-d; Fig 13c; Fig 13e). Calculating the ratio of HSPC normal hemaotopoietic regeneration (%hCD45+) to AML leukemogenesis (%CD33+hCD45+ blasts) revealed that thioridazine significantly reduced LSC function while preserving normal HSC capacity (Fig 12e). In the absence of thioridazine, no difference in the level of leukemic engraftment of secondary transplant recipients was observed. This suggests that continued exposure to this drug is necessary to inhibit leukemogenesis in secondary recipients. These data demonstrate that thioridazine selectively targets somatic CSCs whilst having no effect on normal SC properties in vivo. As thioridazine was identified through the use of a novel differential screening platform using normal and neoplastic hPSCs in vitro, the functional effects of thioridazine provide an example of the predictive value of using human PSCs to understand somatic CSCs. </p><p id="p0206" num="0206"> Example 11 : Dopamine receptors demarcate human CSCs </p><p id="p0207" num="0207">[00121] Thioridazine is known to act through the dopamine receptors (DR 1-5) (Beaulieu and Gainetdinov, 201 1 ; Seeman and Lee, 1975). To 
<!-- EPO <DP n="45"/>-->
 assess whether the mechanism of thioridazine action to selectively interfere with human CSCs vs. normal SCs is via DR antagonism, DR cell surface expression was analyzed. To date, five DRs have been identified and divided into Drfamily (D1 and D5) and D<sub>2</sub>-family (D2, D3, and D4) receptors (Sibley and Monsma, 1992). Normal hPSCs expressing the pluripotent marker SSEA3 were devoid of DR expression (Fig 14a and Fig 15a-b). In contrast, neoplastic hPSCs expressed all five DRs (Fig 14b). The observed differential expression of DRs and the selective inhibition of thioridazine for neoplastic hPSCs suggest that inhibition of DR signaling may play a role in selective targeting of human CSCs vs. normal SCs. </p><p id="p0208" num="0208"> [00122] To expand the potential role of DRs in CSCs based on the functional role of thioridazine treatment we examined whether DR antagonism could account for the loss of LSC function following thioridazine treatment. Expression of DR1 -5 was analyzed in HSPCs (Fig 14c) and human hematopoietic mononuclear cells from normal CB (Figs 15c-f) and AML patient samples (Fig 14d and Fig 15g). DRs were not observed in the primitive HSCs or progenitor populations of CB (identified as the CD34+38- or CD34+38+ fractions, respectively (Bhatia et al., 1997)) (Fig 14c) indicating that HSCs and progenitors do not express the targets for thioridazine. Similarly, DRs were undetectable on the surface of erythroid (Fig 15c), megakaryocyte (Fig 15c), and lymphoid cells (Fig 15d). Only monocytes defined as CD14+ and approximately half the population of granulocytes defined as CD15+ expressed DRs (Figs 15e-f). All of the 13 AML patient samples analyzed contained a population of DR+ blasts with varying levels of all five receptors (Fig 14d) and were predominately detected in CD34+/CD14+ cells (Fig 15g). However, unlike normal HSCs, CD34+ cells do not correlate with LSC capacity in human AML (Taussig et al., 2008) and have recently been identified in numerous subfractions devoid of CD34 or CD38 (Eppert et al., 201 1 ). Observations of differential DR expression in normal and AML human hematopoietic samples strongly suggest the human AML LSCs are heterogeneous and drug targeting should be based on molecular pathways instead of surrogate phenotype predications. 
<!-- EPO <DP n="46"/>-->
 [00123] Aside from hematopoietic tissue, somatic CSCs have recently been identified and validated in human breast tumors and have a CD44+CD24-/lo phenotype (Al-Hajj et al., 2003). Using primary human breast tumors which test negative for estrogen receptor (ER-), progesterone receptor (PR-), and human epidermal receptor 2 (HER2-) that are associated with the poorest prognostic outcomes (Dent et al., 2007) we reveal DR colocalization on the CD44+CD24-/lo breast CSCs (n=3 patients) (Figs 14e-f and Fig 15h). This finding is consistent with the low levels of DRs found in normal mammary gland tissue, whereas benign breast tumors show intermediate levels and breast cancers display high levels of these receptors (Carlo, 1986). Whether the DR expression in AML-blasts was correlative to incidence of LSCs in AML patients was investigated. AML samples with a large fraction of DRD3+ blasts (Fig 14g) and DRD5+ blasts (Fig 14h) contain LSCs as they are able to initiate leukemia in xenotransplantation recipients, unlike AML patient samples with significantly lower levels of DRs that do not contain LSCs. Samples from AML patients containing LSCs have been correlated to poor prognostic outcome while non-LSC samples demonstrate a good prognosis (Eppert et al., 201 1 ). High levels of DR expression correlate with poor prognosis while low levels demonstrate good prognosis (Fig 14g-h) suggesting that DR assessment has prognostic biomarker applications and is less complex than molecular signatures or LSC readouts for each AML patient. Based on initial identification in neoplastic hPSCs, these collective results suggest a potentially more generalizable role for DR expression in human somatic CSCs than anticipated, and validate DR as a candidate biomarker for other CSCs in the human. </p><p id="p0209" num="0209"> Example 12: Thioridazine antagonism of DR inhibits human AML </p><p id="p0210" num="0210"> [00124] To better understand the functional role of DR in human AML, two AML cell lines derived from patients; AML-OCI2 and AML-OCI3, were utilized (Koistinen et al., 2001 ). </p><p id="p0211" num="0211">[00125] Like primary samples, these two cell lines revealed expression for each DR1 -5 (Fig 16a) at markedly higher levels than seen in patient 
<!-- EPO <DP n="47"/>-->
 samples. Due to the bioavailability of dopamine in fetal bovine serum (FBS) (Little et al., 2002), serum-free conditions were employed to assess the role of DRs in AML. Both AML lines were treated with thioridazine and compared to other known DR antagonists clozapine and chlorpromazine (Seeman and Lee, 1975). All three DR antagonists reduced the number of AML cells upon treatment (Fig 16b). To further evaluate the specificity of DR targeting on human AML cells, patient AML samples were divided into DR+ and DR- subfractions using fluorescence activated cell sorting before being treated with DMSO vehicle or thioridazine for 24h and then assayed for blast- CFU content. A reduction in blast-CFU generation was only observed in the DR+ subfraction treated with thioridazine (Fig 17a) whereas no reduction was observed in DR- subfraction treated with thioridazine (Fig 17b). Conversely, the addition of a DR D2-family agonist, 70H-DPAT, increased the number of AML cells (Fig 16c). DR D2-family and D -family exert opposing actions on intracellular signaling leading to differential biological effects (Self et al., 1996). Treatment with a DR D1 -family agonist, SKF38393, resulted in a significant reduction in AML cell number confirming that D2-family signaling is necessary for AML cell survival (Fig 16d). These combined results suggest the mechanism of thioridazine's action is through antagonism of D2-family DRs and not due to off-target effects, and identifies a novel avenue of CSC targeting via DR signaling. </p><p id="p0212" num="0212"> [00126] While the present disclosure has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the disclosure is not limited to the disclosed examples. To the contrary, the disclosure is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims. </p><p id="p0213" num="0213"> [00127] All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety. 
<!-- EPO <DP n="48"/>-->
 [00128] References: </p><p id="p0214" num="0214"> Adewumi, O., Aflatoonian, B., Ahrlund-Richter, L., Amit, M., Andrews, P. W., Beighton, G., Bello, PA, Benvenisty, N., Berry, L S., Bevan, S., et al. (2007). Characterization of human embryonic stem cell lines by the </p><p id="p0215" num="0215">International Stem Cell Initiative. Nat Biotechnol 25, 803-816. </p><p id="p0216" num="0216"> Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., and Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100, 3983-3988. </p><p id="p0217" num="0217"> Beaulieu, J. M., and Gainetdinov, R. R. (201 1 ). The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63, 182- 217. </p><p id="p0218" num="0218"> Ben-Porath, I., Thomson, M. W., Carey, V. J., Ge, R., Bell, G. W., Regev, A., and Weinberg, R. A. (2008). An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40, 499-507. </p><p id="p0219" num="0219"> Bhatia, M., Wang, J. C, Kapp, U., Bonnet, D., and Dick, J. E. </p><p id="p0220" num="0220">(1997). Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci U S A 94, 5320- 5325. </p><p id="p0221" num="0221"> Bonnet, D., and Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell.</p><p id="p0222" num="0222">Nat Med 3, 730-737. </p><p id="p0223" num="0223"> Boyer, L. A., Lee, T. I., Cole, M. F., Johnstone, S. E., Levine, S. S.,</p><p id="p0224" num="0224">Zucker, J. P., Guenther, M. G., Kumar, R. M., Murray, H. L, Jenner, R. G., et al. (2005). Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122, 947-956. </p><p id="p0225" num="0225"> Breitman, T. R., Collins, S. J., and Keene, B. R. (1981 ). Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood 57, 1000-1004. </p><p id="p0226" num="0226"> Breitman, T. R., Selonick, S. E., and Collins, S. J. (1980). Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A 77, 2936-2940. </p><p id="p0227" num="0227"> Burnett, A. K., Hills, R. K., Green, C, Jenkinson, S., Koo, K., Patel, Y.,</p><p id="p0228" num="0228">Guy, C, Gilkes, A., Milligan, D. W., Goldstone, A. H., et al. (2010). The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in</p><p id="p0229" num="0229">NPM1 , FLT3, and CEBPA Blood 115, 948-956. </p><p id="p0230" num="0230"> Carlo, R. D., Muccioli, G., Bellussi, G., Portaleone, P., Ghi, P., Racca, S. and Carlo, F. D. (1986). Steroid, Prolactin, and Dopamine Receptors in 
<!-- EPO <DP n="49"/>-->
 Normal and Pathologic Breast Tissue. Annals of the New York Academy of Sciences 464, 559-562. </p><p id="p0231" num="0231"> Chadwick, K., Wang, L, Li, L, Menendez, P., Murdoch, B., Rouleau, A., and Bhatia, M. (2003). Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic stem cells. Blood 102, 906-915. </p><p id="p0232" num="0232"> Dalton, S. O., Johansen, C, Poulsen, A. H., Norgaard, M., Sorensen, H. T., McLaughlin, J. K., Mortensen, P. B., and Friis, S. (2006). Cancer risk among users of neuroleptic medication: a population-based cohort study. Br J Cancer 95, 934-939. </p><p id="p0233" num="0233"> Dalton, S. O., Mellemkjaer, L., Thomassen, L, Mortensen, P. B., and</p><p id="p0234" num="0234">Johansen, C. (2005). Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969-1993. Schizophr Res 75,315-324. </p><p id="p0235" num="0235"> Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A.,Rawlinson, E., Sun, P., and Narod, S. A. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13, 4429-4434. </p><p id="p0236" num="0236"> Desbordes, S. C, Placantonakis, D. G., Ciro, A., Socci, N. D., Lee, G., Djaballah, H., and Studer, L. (2008). High-throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells. Cell Stem Cell 2, 602-612. </p><p id="p0237" num="0237"> Diallo, J. S., Le Boeuf, F., Lai, F., Cox, J., Vaha-Koskela, M., </p><p id="p0238" num="0238">Abdelbary, H., MacTavish, H., Waite, K., Falls, T., Wang, J., et al. (2010). A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol Ther 18, 1 123-1 129. </p><p id="p0239" num="0239"> Dick, J. E. (2008). Stem cell concepts renew cancer research. Blood</p><p id="p0240" num="0240">112, 4793-4807. </p><p id="p0241" num="0241"> Dick, J. E. (2009). Looking ahead in cancer stem cell research. Nat Biotechnol 27, 44-46. </p><p id="p0242" num="0242"> Driver, J. A., Logroscino, G., Buring, J. E., Gaziano, J. M., and Kurth, T. (2007). A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease. Cancer Epidemiol Biomarkers Prev 16, 1260-1265. </p><p id="p0243" num="0243"> Eppert, K., Takenaka, K., Lechman, E. R., Waldron, L., Nilsson, B., van Galen, P., Metzeler, K. H., Poeppl, A., Ling, V., Beyene, J., et al. (201 1 ). Stem cell gene expression programs influence clinical outcome in human leukemia. Nature Medicine doi:10.1038/nm.2415. </p><p id="p0244" num="0244"> Estey, E., and Dohner, H. (2006). Acute myeloid leukaemia. Lancet 368, 1894-1907. </p><p id="p0245" num="0245"> Fibach, E., Hayashi, M., and Sachs, L. (1973). Control of normal differentiation of myeloid leukemic cells to macrophages and granulocytes. Proc Natl Acad Sci U S A 70, 343-346. 
<!-- EPO <DP n="50"/>-->
 Frese, K. K., and Tuveson, D. A. (2007). Maximizing mouse cancer models. Nat Rev Cancer 7, 645-658. </p><p id="p0246" num="0246"> Friend, C, Scher, W., Holland, J. G., and Sato, T. (1971 ). </p><p id="p0247" num="0247">Hemoglobin synthesis in murine virus- induced leukemic cells in vitro: </p><p id="p0248" num="0248">stimulation of erythroid differentiation by dimethyl sulfoxide. Proc Natl Acad Sci U S A 68, 378-382. </p><p id="p0249" num="0249"> Guan, Y., Gerhard, B., and Hogge, D. E. (2003). Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 101, 3142-3149. </p><p id="p0250" num="0250"> Gupta, P. B., Onder, T. T., Jiang, G., Tao, K., Kuperwasser, C,</p><p id="p0251" num="0251">Weinberg, R. A., and Lander, E. S. (2009). Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645-659. </p><p id="p0252" num="0252"> Hotta, A., Cheung, A. Y., Farra, N., Vijayaragavan, K., Seguin, C. A., Draper, J. S., Pasceri, P., Maksakova, I. A., Mager, D. L., Rossant, J., er a/. (2009). Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency. Nat Methods 6, 370-376. </p><p id="p0253" num="0253"> Inglese, J., Shamu, C. E., and Guy, R. K. (2007). Reporting data from high-throughput screening of small-molecule libraries. Nat Chem Biol 3, 438- 441. </p><p id="p0254" num="0254"> Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010). Cancer statistics,</p><p id="p0255" num="0255">20 0. CA Cancer J Clin 60, 277-300. </p><p id="p0256" num="0256"> Jordan, C. T. (2009). Cancer stem cells: controversial or just misunderstood? Cell Stem Cell 4, 203-205. </p><p id="p0257" num="0257"> Koistinen P et al., Regulation of the acute myeloid leukemia cell line OCI/AML-2 by endothelial nitric oxide synthase under the control of a vascular endothelial growth factor signaling system. Leukemia. 2001 Sep; 15(9): 1433- 41. </p><p id="p0258" num="0258"> Lapidot, T., Sirard, C, Vormoor, J., Murdoch, B., Hoang, T., Caceres-</p><p id="p0259" num="0259">Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., and Dick, J. E. (1994). A cell initiating human acute myeloid leukaemia after transplantation into</p><p id="p0260" num="0260">SCID mice. Nature 367, 645-648. </p><p id="p0261" num="0261"> Lee, J. Y., Nakada, D., Yilmaz, O. H., Tothova, Z., Joseph, N. M.,</p><p id="p0262" num="0262">Lim, M. S„ Gilliland, D. G., and Morrison, S. J. (2010). mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Cell Stem Cell 7, 593-605. </p><p id="p0263" num="0263"> Li, X., Lewis, M. T., Huang, J., Gutierrez, C, Osborne, C. K., Wu, M. F.,</p><p id="p0264" num="0264">Hilsenbeck, S. G., Pavlick, A., Zhang, X., Chamness, G. C, er a/. (2008).</p><p id="p0265" num="0265">Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl</p><p id="p0266" num="0266">Cancer Inst 100, 672-679. </p><p id="p0267" num="0267"> Little, K. Y., Elmer, L. W., Zhong, H., Scheys, J. O., and Zhang, L.</p><p id="p0268" num="0268">(2002). Cocaine induction of dopamine transporter trafficking to the plasma membrane. Mol Pharmacol 61, 436-445. 
<!-- EPO <DP n="51"/>-->
 Nasr, R., Guillemin, M. C, Ferhi, O., Soilihi, H., Peres, L, Berthier,</p><p id="p0269" num="0269">C, Rousselot, P., Robledo- Sarmiento, M., Lallemand-Breitenbach, V., Gourmel, B., et al. (2008). Eradication of acute promyelocytic leukemia- initiating cells through PML-RARA degradation. Nat Med 14, 1333-1342. </p><p id="p0270" num="0270"> Nichols, J., Zevnik, B., Anastassiadis, K., Niwa, H., Klewe-Nebenius,</p><p id="p0271" num="0271">D. , Chambers, I., Scholer, H., and Smith, A. (1998). Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 95, 379-391. </p><p id="p0272" num="0272"> Niu, C, Yan, H., Yu, T., Sun, H. P., Liu, J. X., Li, X. S., Wu, W., Zhang, F. Q., Chen, Y., Zhou, L., er al. (1999). Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 1 1 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94, 3315-3324. </p><p id="p0273" num="0273"> Niwa, H., Miyazaki, J., and Smith, A. G. (2000). Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24, 372-376. </p><p id="p0274" num="0274"> Raj, L., Ide, T., Gurkar, A. U., Foley, M., Schenone, M., Li, X., Tolliday, N. J., Golub, T. R., Carr, S. A., Shamji, A. F., et al. (201 1 ). Selective killing of cancer cells by a small molecule targeting the stress response to ROS. </p><p id="p0275" num="0275">Nature 475, 231-234. </p><p id="p0276" num="0276"> Recher, C, Beyne-Rauzy, O., Demur, C, Chicanne, G., Dos </p><p id="p0277" num="0277">Santos, C, Mas, V. M., Benzaquen, D., Laurent, G., Huguet, F., and </p><p id="p0278" num="0278">Payrastre, B. (2005). Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105, 2527-2534. </p><p id="p0279" num="0279"> Reya, T., Morrison, S. J., Clarke, M. F., and Weissman, I. L. (2001 ).</p><p id="p0280" num="0280">Stem cells, cancer, and cancer stem cells. Nature 414, 105-1 1 1. </p><p id="p0281" num="0281"> Sachs, L. (1978a). Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia. Nature 274, 535- 539. </p><p id="p0282" num="0282"> Sachs, L. (1978b). The differentiation of myeloid leukaemia cells: new possibilities for therapy. Br J Haematol 40, 509-517. </p><p id="p0283" num="0283"> Sanz, M. A. (2006). Treatment of acute promyelocytic leukemia. </p><p id="p0284" num="0284">Hematology Am Soc Hematol Educ Program, 147-155. </p><p id="p0285" num="0285"> Sanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Buchner, T., Dohner, H., et al. (2009). Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113, 1875-1891. </p><p id="p0286" num="0286"> Seeman, P., and Lee, T. (1975). Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188, 1217-1219. 
<!-- EPO <DP n="52"/>-->
 Self, D. W., Barnhart, W. J., Lehman, D. A., and Nestler, E. J. (1996). Opposite modulation of cocaine- seeking behavior by D1- and D2-like dopamine receptor agonists. Science 271, 1586-1589. </p><p id="p0287" num="0287"> Shoemaker, R. H. (2006). The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6, 813-823. </p><p id="p0288" num="0288"> Sibley, D. R., and Monsma, F. J., Jr. (1992). Molecular biology of dopamine receptors. Trends Pharmacol Sci 13, 61 -69. </p><p id="p0289" num="0289"> Smith, B. D., Levis, M., Beran, M., Giles, F., Kantarjian, H., Berg, K., Murphy, K. M., Dauses, T.,Allebach, J., and Small, D. (2004). Single-agent CEP-701 , a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103, 3669- 3676. </p><p id="p0290" num="0290"> Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L, Bennett, C. L, Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006). 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24, 3187-3205. </p><p id="p0291" num="0291"> Taussig, D. C, Miraki-Moud, F., Anjos-Afonso, F., Pearce, D. J., Allen, K., Ridler, C, Lillington, D., Oakervee, H., Cavenagh, J., Agrawal, S. G., et al. (2008). Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. </p><p id="p0292" num="0292">Blood 112, 568-575. </p><p id="p0293" num="0293"> Tefferi et al. Cancer, September 1<sup>st</sup>, pp. 3842-3847 (2009) </p><p id="p0294" num="0294"> Vannucchi et al. Advances in Understanding and Management of Myeloproliferative Neoplasms CA Cancer J. Clin. 2009; 59:171-191 </p><p id="p0295" num="0295"> Visvader, J. E., and Lindeman, G. J. (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8, 755-768. </p><p id="p0296" num="0296"> Wang, Z. Y., and Chen, Z. (2008). Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111, 2505-2515. </p><p id="p0297" num="0297"> Werbowetski-Ogilvie, T. E., Bosse, M., Stewart, M., Schnerch, A., Ramos-Mejia, V., Rouleau, A., Wynder, T., Smith, M. J., Dingwall, S., Carter, T., et al. (2009). Characterization of human embryonic stem cells with features of neoplastic progression. Nat Biotechnol 27, 91 -97. </p><p id="p0298" num="0298"> Xu, R. H., Chen, X., Li, D. S., Li, R., Addicks, G. C, Glennon, C,</p><p id="p0299" num="0299">Zwaka, T. P., and Thomson, J. A. (2002). BMP4 initiates human </p><p id="p0300" num="0300">embryonic stem cell differentiation to trophoblast. Nat Biotechnol 20, </p><p id="p0301" num="0301">1261-1264. </p><p id="p0302" num="0302"> Yilmaz, O. H., Valdez, R., Theisen, B. K., Guo, W., Ferguson, D. O., Wu, H., and Morrison, S. J. (2006). Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441 , 475- 482. 
<!-- EPO <DP n="53"/>-->
 Ying, Q. L, Nichols, J., Chambers, I., and Smith, A. (2003). BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 115, 281-292. </p><p id="p0303" num="0303"> Yoshida, H., Kitamura, K., Tanaka, K., Omura, S., Miyazaki, T., Hachiya, T., Ohno, R., and Naoe, T. (1996). Accelerated degradation of PML- retinoic acid receptor alpha (PML-RARA) oncoprotein by all- trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res 56, 2945-2948. </p><p id="p0304" num="0304"> Zhelev, Z., Ohba, H., Bakalova, R., Hadjimitova, V., Ishikawa, M., Shinohara, Y., and Baba, Y. (2004).Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. Phenothiazines and leukemia. Cancer Chemother Pharmacol 53, 267-275. </p><p id="p0305" num="0305"> Zheng, R., Friedman, A. D., and Small, D. (2002). Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations. Blood 100, 4154-4161. </p><p id="p0306" num="0306"> Zhu, J., Koken, M. H., Quignon, F., Chelbi-Alix, M. K., Degos, L, Wang, Z. Y., Chen, Z., and de The, H. (1997). Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of </p><p id="p0307" num="0307">acutepromyelocytic leukemia. Proc Natl Acad Sci U S A 94, 3978-3983. 
</p></description><claims mxw-id="PCLM44852908" ref-ucid="WO-2012116432-A1" lang="EN" load-source="patent-office"><claim-statement><!-- EPO <DP n="54"/>-->Claims: </claim-statement><claim id="clm-0001" num="1"><claim-text>1. A method of treating acute myeloid leukemia (A L) in a subject comprising administering to the subject a dopamine receptor antagonist. </claim-text></claim><claim id="clm-0002" num="2"><claim-text>2. The method of claim 1 , wherein the dopamine receptor antagonist is a D<sub>2</sub> family dopamine receptor antagonist. </claim-text></claim><claim id="clm-0003" num="3"><claim-text>3. The method of claim 2, wherein the dopamine receptor antagonist is a phenothiazine derivative or a compound listed in Table 1. </claim-text></claim><claim id="clm-0004" num="4"><claim-text>4. The method of claim 3, wherein the phenothiazine derivative is thioridazine. </claim-text></claim><claim id="clm-0005" num="5"><claim-text>5. The method of any one of claims 1 to 4, wherein the acute myeloid leukemia comprises cells that express one or more dopamine receptors (DR) selected from DR1 , DR2, DR3, DR4 and DR5. </claim-text></claim><claim id="clm-0006" num="6"><claim-text>6. The method of claim 5, wherein the cells that express one or more dopamine receptors also express CD14. </claim-text></claim><claim id="clm-0007" num="7"><claim-text>7. The method of any one of claims 1 to 6, wherein the dopamine receptor antagonist preferentially induces the differentiation of cancer stem cells relative to hematopoietic or normal stem cells. </claim-text></claim><claim id="clm-0008" num="8"><claim-text>8. The method of any one of claims 1 to 7, wherein the subject is in remission. </claim-text></claim><claim id="clm-0009" num="9"><claim-text>9. A method for reducing the proliferation of a cancer cell comprising contacting the cancer cell with a dopamine receptor antagonist. </claim-text></claim><claim id="clm-0010" num="10"><claim-text>10. The method of claim 9, wherein the cancer cell is a cancer stem cell and contacting the cancer stem cell with the dopamine receptor antagonist induces differentiation of the cancer stem cell. <!-- EPO <DP n="55"/>--> </claim-text></claim><claim id="clm-0011" num="11"><claim-text>1 1. The method of claim 9 or 10, wherein the cancer cell is an acute myeloid leukemia (AML) cell. </claim-text></claim><claim id="clm-0012" num="12"><claim-text>12. The method of any one of claims 9 to 1 1 , wherein the cell is in vivo or in vitro. </claim-text></claim><claim id="clm-0013" num="13"><claim-text>13. The method of any one of claims 9 to 12, wherein the dopamine receptor antagonist is a D<sub>2</sub> family dopamine receptor antagonist. </claim-text></claim><claim id="clm-0014" num="14"><claim-text>14. The method of any one of claims 9 to 13, wherein the dopamine receptor antagonist is a phenothiazine derivative or a compound listed in Table 1. </claim-text></claim><claim id="clm-0015" num="15"><claim-text>15. The method of claim 14, wherein the phenothiazine derivative is thioridazine. </claim-text></claim><claim id="clm-0016" num="16"><claim-text>16. A method of identifying a subject with cancer suitable for treatment with a dopamine receptor antagonist, the method comprising determining the expression of one or more dopamine receptors in a sample of cancer cells from the subject, whereby subjects with cancer cells that express one or more dopamine receptors are identified as suitable for treatment with the dopamine receptor antagonist. </claim-text></claim><claim id="clm-0017" num="17"><claim-text>17. The method of claim 16, wherein the step of determining the expression of one or more dopamine receptors in the sample comprises testing the sample for levels of polynucleotides or polypeptides that code for one or more dopamine receptors. </claim-text></claim><claim id="clm-0018" num="18"><claim-text>18. The method of claim 16 or 17, wherein the one or more dopamine receptors are selected from DR1 , DR2, DR3, DR4 and DR5. </claim-text></claim><claim id="clm-0019" num="19"><claim-text>19. The method of claim 18, wherein the one or more dopamine receptors include D2 family dopamine receptors. </claim-text></claim><claim id="clm-0020" num="20"><claim-text>20. The method of any one of claims 16 to 19, wherein the cancer is leukemia or breast cancer. <!-- EPO <DP n="56"/>--> </claim-text></claim><claim id="clm-0021" num="21"><claim-text>21. The method of claim 20, wherein the cancer is acute myeloid leukemia or monocytic leukemia. </claim-text></claim><claim id="clm-0022" num="22"><claim-text>22. A method of determining a prognosis for a subject with cancer, the method comprising: </claim-text><claim-text> determining a level of expression of one or more biomarkers selected from dopamine receptor (DR) 1 , DR2, DR3, DR4 and DR5 in a sample from the subject, and </claim-text><claim-text> comparing the level of expression of the one or more biomarkers to a control, wherein an increased level of expression of the one or more biomarkers relative to the control indicates that the subject has a more severe form of cancer. </claim-text></claim><claim id="clm-0023" num="23"><claim-text>23. The method of claim 22, wherein the step of determining the expression of one or more biomarkers in the sample comprises testing the sample for levels of polynucleotides or polypeptides that code for the one or more biomarkers. </claim-text></claim><claim id="clm-0024" num="24"><claim-text>24. The method of claim 22 or 23, wherein the biomarkers are DR3 and/or DR5. </claim-text></claim><claim id="clm-0025" num="25"><claim-text>25. The method of any one of claims 22 to 24, wherein the cancer is leukemia and an increased expression of one or more biomarkers compared to the control indicates a more severe form of leukemia. </claim-text></claim><claim id="clm-0026" num="26"><claim-text>26. The method of claim 25, wherein the leukemia is acute myeloid leukemia or monocytic leukemia. </claim-text></claim><claim id="clm-0027" num="27"><claim-text>27. A method for identifying a subject with leukemia comprising: </claim-text><claim-text> determining a level of expression of one or more biomarkers selected from dopamine receptor (DR) 1 , DR2, DR3, DR4 and DR5 in a sample of white blood cells from the subject, and <!-- EPO <DP n="57"/>--> comparing the level of expression of the one or more biomarkers to a control. </claim-text></claim><claim id="clm-0028" num="28"><claim-text>28. The method of claim 27, wherein an increased level of expression of one or more dopamine receptors compared to the control is indicative of a subject with leukemia. </claim-text></claim><claim id="clm-0029" num="29"><claim-text>29. The method of claim 28, wherein the leukemia is acute myeloid leukemia or monocytic leukemia. </claim-text></claim><claim id="clm-0030" num="30"><claim-text>30. A method of screening compounds for anti-cancer activity comprising: identifying compounds that antagonize one or more dopamine receptors, wherein compounds that antagonize dopamine receptors are identified as having anti-cancer activity. </claim-text></claim><claim id="clm-0031" num="31"><claim-text>31. The method of claim 30, wherein the anti-cancer activity comprises reduced proliferation of breast cancer cells, AML cells or monocytic cells. </claim-text></claim><claim id="clm-0032" num="32"><claim-text>32. A method for identifying a cancer stem cell from a population of cells, the method comprising: </claim-text><claim-text> determining whether a cell expresses one or more biomarkers selected from dopamine receptor (DR) 1 , DR2, DR3, DR4 and DR5; </claim-text><claim-text> wherein expression of the one or more biomarkers is indicative that the cell is a cancer stem cell. </claim-text></claim><claim id="clm-0033" num="33"><claim-text>33. The method of claim 32, wherein the population of cells comprises cells isolated from a mammal or cells in tissue culture. </claim-text></claim><claim id="clm-0034" num="34"><claim-text>34. The method of claim 32 or 33, wherein the population of cells comprises pluripotent stem cells. </claim-text></claim><claim id="clm-0035" num="35"><claim-text>35. The method of any one of claims 32 to 34, wherein the population of cells comprises cancer cells or pre-cancerous cells such as leukemic cells or breast cancer cells. <!-- EPO <DP n="58"/>--> </claim-text></claim><claim id="clm-0036" num="36"><claim-text>36. The method of any one of claims 32 to 35, wherein the population of cells comprises hematological cancer cells. </claim-text></claim><claim id="clm-0037" num="37"><claim-text>37. The method of any one of claims 32 to 36, wherein the step of determining whether the cell expresses one or biomarkers comprises testing the cell for the expression of polynucleotides or polypeptides that code for DR1 , DR2, DR3, DR4 or DR5. </claim-text></claim><claim id="clm-0038" num="38"><claim-text>38. The method of any one of claims 32 to 37, wherein a cell that expresses DR1 , DR2, DR3, DR4 and DR5 is identified as a cancer stem cell. </claim-text></claim><claim id="clm-0039" num="39"><claim-text>39. The method of any one of claims 32 to 38, further comprising isolating the cancer stem cells from the population of cells. </claim-text></claim><claim id="clm-0040" num="40"><claim-text>40. The method of claim 39, wherein the step of isolating the cancer stem cells form the population of cells comprises flow cytometry, fluorescence activated cell sorting, panning, affinity column separation, or magnetic selection. </claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
